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PREAMBLE
This document has been developed as a Clinical Expert
Consensus Document (CECD), combining the resources of
the American College of Cardiology (ACC) and the Society
for Cardiac Angiography and Interventions (SCA&I). It is
intended to provide a perspective on the current state of
cardiac catheterization and the laboratories in which these
procedures are performed. Clinical Expert Consensus Doc-
uments are intended to inform practitioners, payers, and
other interested parties of the opinion of the ACC concern-
ing evolving areas of clinical practice and/or technologies
that are widely available or new to the practice community.
Topics chosen for coverage by expert consensus documents
are so designed because the evidence base, experience with
technology and/or clinical practice are not considered suf-
ficiently well developed to be evaluated by the formal
ACC/American Heart Association (AHA) Practice Guide-
lines process. Often the topic is the subject of considerable
ongoing investigation. Thus, the reader should view the
CECD as the best attempt of the ACC to inform and guide
clinical practice in areas where rigorous evidence may not
yet be available or the evidence to date is not widely
accepted. Where feasible, CECDs include indications or
contraindications. Some topics covered by CECDs will be
addressed subsequently by the ACC/AHA Practice Guide-
lines Committee.
The Task Force on CECDs makes every effort to avoid
any actual or potential conflicts of interest that might arise
as a result of an outside relationship or personal interest of
a member of the writing panel. Specifically, all members of
the writing panel are asked to provide disclosure statements
of all such relationships that might be perceived as real or
potential conflicts of interest to inform the writing effort.
Robert A. O’Rourke, MD, FACC
Chair, ACC Task Force on Clinical Expert Consensus Documents
EXECUTIVE SUMMARY
A. The Cardiac Catheterization Laboratory Environment
Cardiac catheterizations are currently performed safely in
hospitals with and without cardiac surgical backup. The
latest information from the SCA&I lists .2,100 cardiac
catheterization laboratories in the U.S. (including Puerto
Rico and the Virgin Islands) (1). Of these, 72% provided
on-site cardiac surgery (including 85% of those performing
coronary intervention). Fifty-eight laboratories were located
in nonhospital settings.
In a hospital with cardiac surgery, essentially all patients
with cardiovascular disease can undergo invasive studies
safely. Full support services include not only cardiovascular
surgery but also vascular surgery, nephrology and dialysis,
neurology, hematology, and specialized imaging services
(e.g., computed tomography, magnetic resonance imaging,
and ultrasound). See Table 7 for assessment of proficiency
criteria for individual operators and cardiac catheterization
laboratories.
In the hospital setting without cardiac surgery capability,
many patients can undergo cardiac procedures safely. Ex-
clusions for cardiac catheterization in this setting include
patients with acute coronary syndromes, severe congestive
heart failure, pulmonary edema due to acute ischemia, a
high likelihood of severe multivessel or left main disease
based on noninvasive testing, and severe left ventricular
dysfunction associated with valvular disease. Certain elective
therapeutic interventional procedures such as percutaneous
coronary interventions (PCIs) and valvuloplasty should still
be performed in facilities that provide cardiac surgical
support. The ACC Competence Statement on Recommen-
dations for the Assessment and Maintenance of Proficiency
in Coronary Interventional Procedures and the ACC/AHA
Guidelines for PCI Procedures (2,3) have addressed the
issue of primary angioplasty for acute myocardial infarction
in hospitals without cardiac surgery capability. Recent data
suggest a lower mortality rate among patients undergoing
primary angioplasty in higher-volume centers (4). Hospitals
that perform primary angioplasty but are without on-site
cardiac surgery capability must have a proven plan for rapid
access (within 1 h) to a cardiac surgical operating room in a
nearby facility with appropriate hemodynamic support ca-
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pability for such a transfer. The procedure should be limited
to patients with ST-segment elevation MI or new LBBB on
ECG, and done in a timely fashion (balloon inflation within
90 6 30 min of admission) by persons skilled in the
procedure ($75 PCIs performed/year) and only in facilities
performing a minimum of 36 primary PCIs/year. In accor-
dance with the soon-to-be-published ACC/AHA guide-
lines for PCI (3), this committee does not endorse the
performance of elective PCI in a facility without cardiac
surgery capability.
Patients are also being studied in freestanding laborato-
ries (i.e., those that are not physically attached to the
hospital). By definition a freestanding laboratory is one
where quick transportation of a patient to a hospital by
gurney is not possible. These patients clearly must be in
stable condition and at the lowest risk for complications. It
is vitally important to have mechanisms for backup and
bailout in place to provide assistance should patients become
unstable in this setting. Although a tertiary hospital serves
as an appropriate means for providing proper oversight of a
freestanding laboratory, recognized credentialing bodies ap-
proved by the local community may be able to provide
appropriate oversight to ensure that all issues related to
quality assurance (QA) are monitored and addressed. Inter-
ventional procedures of any kind should not be performed in
a freestanding facility.
B. Same-Day and Outpatient Cardiac Catheterization
With the decline in risk associated with cardiac catheter-
ization, the performance of invasive procedures in the
ambulatory setting has become more popular. However,
prehospitalization may still be important in patients receiv-
ing anticoagulation therapy or in those with renal failure,
diabetes, or a contrast allergy. Early discharge after the
procedure may also be inappropriate for certain patients,
including those with a procedure-related complication or
hemodynamic instability. In addition, some patients are best
observed overnight if severe disease is discovered (e.g.,
significant left main coronary artery disease or severe aortic
stenosis) or in the presence of significant comorbid diseases
that increase the risk of late complications. A general
scheme is presented to help determine who should be
excluded from early discharge after cardiac catheterization.
C. QA Issues
Quality assurance starts with an assessment of clinical
proficiency among the operators in the cardiac catheteriza-
tion laboratory. This is surely one of the most difficult
elements to assess, but issues of cognitive knowledge,
procedural skill, clinical judgment, and procedural outcomes
are all important. QA extends to the performance of the
laboratory as a whole. A continuous quality-improvement
(QI) program should also be included in the laboratory’s
overall design.
One measure of outcome is the number of “normal”
diagnostic cardiac catheterizations performed. “Normal” in
this regard refers to no disease or insignificant (,50%
diameter narrowing) coronary stenoses in patients studied
primarily for the identification of coronary artery lesions. It
is recognized that there is a difference between coronary
arteries that are completely normal and those that have
insignificant luminal stenoses. It is further recognized that
coronary disease is a dynamic process and that endothelial
dysfunction may contribute to certain clinical syndromes. In
some laboratories “normal” coronary arteries may be espe-
cially prevalent because the patient mix includes a variety
of disease states where coronary disease is not the major
concern such as cardiomyopathy and valvular disease. The
rate of “normals” identified as either insignificant or no
obvious luminal narrowing should be in the range of 20% to
27% if proper screening and baseline decision making is
operative prior to the catheterization.
Outcomes related to complications for diagnostic cathe-
terization should be very low–,1%. Diagnostic accuracy
and adequacy are obviously important parameters as well,
though they are rarely tracked. In the interventional cardiac
catheterization laboratory the acceptable complication rates
are more difficult to gauge, since measures of assessing
high-risk patients have not been standardized. Major com-
plications, (i.e., death, acute myocardial infarction, and
emergency bypass surgery) from interventional procedures
should be ,3%.
The minimum number of studies needed to confirm
adequate skills in cardiac diagnostic catheterization proce-
dures has never been validated. Given the low risk of
diagnostic catheterization, the QI system should be opera-
tive and should hold precedence over any arbitrary figures
proposed in this setting. The Committee could find no data
to support the prior recommendation for a minimum
caseload of 150 catheterizations performed by an individual
per year. A minimum interventional caseload is 75 cases/
year per operator and ideally 400 cases/year for the labora-
tory. Because of the direct correlation between both labo-
ratory and physician volume and outcomes, a low-volume
operator (,75 cases/year) should only work in a high-
volume laboratory (.600 cases/year), and even then with
mentoring. Low-volume operators in any other setting should
not perform interventional procedures. The minimum case-
load for operators performing pediatric catheterizations
has not been established by data, although a caseload of
50/year has been suggested for individual operators. Pedi-
atric cardiac catheterization laboratories often share space
with adult procedural facilities. The pediatric catheteriza-
tion laboratory should perform at least 75 procedures/year.
Equipment maintenance and management remain an
issue, and certain guidelines are provided. Each aspect of the
radiographic system should be able to meet these perfor-
mance expectations. The same is true for the physiological
recorders and other specific devices used in the laboratories.
A QI program must be in place. The keys are to develop
variables that reflect the quality of care, to collect these
variables in a systematic manner, to have a means for
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statistical analysis of the results, and to develop an approach
to problem solving that involves feedback on the effective-
ness of the solutions. These programs should provide
ongoing educational opportunities for staff as well. The
Committee also strongly encourages all laboratories to
participate in a national data registry to help benchmark
their results and provide an ongoing system for tracking
complications.
D. Procedural Issues
Although no rigid protocol is applicable to all laborato-
ries, certain procedural issues are worthy of comment.
Patient preparation generally entails premedication with
mild sedatives. During the procedure a conscious-sedation
protocol should be followed.
Patients with contrast allergies should receive nonionic
contrast and should be premedicated with steroids. Many
laboratories also use antihistamines.
Patients with renal insufficiency should be adequately
hydrated before and after the procedure. A minimal amount
of radiographic contrast should be used along with biplane
angiography when available. There is suggestive evidence
that nonionic radiographic contrast may help reduce the
incidence of nephrotoxicity. Initial studies using pretreat-
ment with acetylcysteine are very promising for the preven-
tion of nephrotoxicity.
Fasting patients with diabetes mellitus should receive a
reduced dose of insulin on the morning of the procedure.
Diabetic patients treated with metformin who have mild
renal insufficiency rarely have been reported to develop
profound lactic acidosis after receiving radiographic con-
trast. Therefore, the metformin dose should be withheld on
the day of the procedure and not restarted until the
creatinine is stable, usually 48 h after the procedure.
Antiplatelet drugs need not be withheld before cardiac
catheterization. Warfarin generally is discontinued until the
international normalized ratio (INR) is ,1.8. It can be
reversed if necessary with vitamin K or fresh frozen plasma.
Patients often undergo cardiac catheterization while receiv-
ing heparin therapy. In-laboratory activated clotting time
(ACT) should be in the range of ’300 s (200 to 250 s if
glycoprotein IIb/IIIa inhibitors are used) during the proce-
dure and ,175 s when the catheters are removed.
Sterile preparation is mandatory for all vascular access
sites. It is important for operators to wear masks, caps, and
eye protection to prevent accidental operator contamination
with blood.
Routine catheterizations of the right side of the heart
should not be performed during diagnostic or interventional
cardiac catheterizations unless specific information of clin-
ical importance is being sought. Routine use of temporary
pacemakers is also inappropriate. In an era of high-quality
echocardiographic methods for assessing left ventricular
function and valvular gradients, there is only an extremely
rare indication for direct left ventricular puncture.
Certain provocative agents may be useful during adult
cardiac catheterization. These include: 1) fluid loading to
assess the hemodynamics associated with constrictive peri-
carditis or restrictive myocardial disease; 2) the use of
afterload alteration or inotropic agents to assess maximal
intraventricular gradients in hypertrophic cardiomyopathy
or in patients with aortic stenosis and low output and low
gradient; 3) the use of coronary vasoactive agents (especially
in combination with coronary flow, pressure, or velocity
measures); 4) the administration of pulmonary vasodilators
in patients with elevated pulmonary vascular resistance; and
5) exercise during the procedure to assess cardiovascular
hemodynamics during stress.
Proper procedural technique includes adequate injection
of the coronary arteries and the use of multiple orthogonal
views with appropriate radiographic angulation for visual-
ization of the various cardiac structures. Pressure measure-
ment requires attention to proper electrical filtering and
patient respiration. Accurate measurement of cardiac output
is difficult in the best of settings, and the vagaries inherent
in all the available methods should be understood to
interpret the results properly.
Postprocedural hemostasis is achievable by a variety of
means, including manual methods, mechanical compression
devices, and percutaneous closure devices. It is important to
monitor the hematoma and pseudoaneurysm rate involving
each method and each device used in any laboratory.
Catheterization reports should contain certain basic in-
formation, and the actual images should be kept for at least
7 years after the study.
E. Personnel Issues
Attending physicians should be credentialed according to
local standards. The laboratory director should have exten-
sive experience (.500 procedures performed over his or her
career). If interventional procedures are performed in the
laboratory, the director should be board certified in inter-
ventional cardiology.
The patient consent form should note if any designees
other than the attending physician are participating in the
procedure. Cardiology trainees (fellows) may be primary
operators with supervision. Physician extenders (physician’s
assistants and nurse practitioners) can participate in cardiac
catheterization procedures along with the attending physi-
cian, but they cannot be primary operators, and all clinical
decision making must reside with credentialed physician
operators.
Other cardiac catheterization personnel include nurse
practitioners, nursing personnel, radiological or physiologi-
cal technologists, and now both darkroom (if cinefilm is
used) and computer specialists. All are critical professionals
and should be treated as such. Continuing education should
be provided for nonphysician staff.
F. Ethical Concerns
Ethical concerns include those related both to clinical
practice and to biomedical research. Rarely do interven-
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tional procedures require 2 cardiologists to be in attendance.
Cardiologists should never receive an admission fee, referral
fee, or other “kickback” for referring a patient to a facility;
this is illegal. Collusion in fixing fees is illegal as well.
Unnecessary services should never be performed or billed.
Cardiologists must avoid any financial business or industry
arrangements that might influence their decision to care for
patients because of personal gain (5). Receipt of direct
remuneration from device, catheter, or drug companies to
use such products is a conflict of interest and should be
avoided. Procedural information should always be presented
honestly, and the collection of procedural outcome data
should be systematic and standardized. Informed consent
should note all participants in the procedure (physician and
physician extenders) and should describe all possible proce-
dures (including ad hoc intervention) should they become a
consideration. Clinical research studies require special at-
tention, with patient safety always overriding other aspects
of any investigational protocol.
G. Imaging Equipment Issues
Radiographic equipment is now evolving after years of
relatively little real change. X-ray tubes with high heat
capacities have become commonplace. Image intensifiers
have continued to improve, with better conversion factors,
improved contrast ratios, less distortion, and better resultant
spatial resolution. Image intensifiers optimized for coronary
angiography may not be optimal for peripheral vascular
imaging. Newer X-ray detectors, such as the flat panel
devices, are being investigated as an alternative to the
current image intensifier. Video cameras are slowly evolving
from the standard 525 3 525 lines per video frame to 1,023
or 1,049 lines with accompanying higher resolution. The
video “pickup tube” is also being replaced by charge-coupled
devices (CCDs) in many systems.
Nearly all new X-ray equipment that is commercially
available allows for digital angiography as cinefilm is grad-
ually phased out. This process should be completed within
the next decade. Elimination of cinefilm has many advan-
tages, including the use of lower framing rates, freeze frames
for roadmapping, immediate availability of images for final
interpretation, improved image playback during the proce-
dure, and elimination of film development, display, and
storage problems. Elimination of cinefilm does not reduce
the X-ray exposure per frame by much, however, as the
primary source of quantum noise is in the X-ray system
itself. Digital systems can reduce X-ray exposure and usage
by reducing framing rates. Pulsing the fluoroscopic dose
helps reduce overall X-ray exposure.
Although the DICOM (Digital Imaging and COmmu-
nication in Medicine) standard has allowed for an accept-
able format and media (the CD-ROM) for exchange of
information between and among cardiac catheterization
laboratories, there is still no uniform standard for short-,
near-, and long-term storage. Many archival options are still
being evaluated. One limitation that older laboratories face
is the availability of an adequate interface that will write the
DICOM standard from X-ray acquisition devices to storage
and retrieval devices. Most digital cardiac systems incorpo-
rate resolutions of 512 3 512 3 8-bit deep images with the
capability of acquiring 30 frames per second (fps). This
results in a minimal spatial resolution in the order of 0.2 to
0.3 mm. Higher matrices such as 1,024 3 1,024 can deliver
resolutions of up to 0.1 to 0.15 mm but at a marked increase
in cost related to data acquisition, storage, and transmission
requirements.
Data compression allows for more rapid transmission of
images over lower bandwidth lines and requires less storage
capacity. Although this is acceptable for many purposes,
clinical errors can occur if lossy compression is used.
Preliminary results from the multicenter clinical study
sponsored by the ACC and the European Society of
Cardiology suggests that only lossless compression (about
2:1 JPEG compression, for instance) should be used for
permanent storage of data and clinical decision making.
Higher compression of images may be used for nonclinical
situations and certain teaching and demonstrative displays
of information.
Digital imaging allows for a practical approach to tele-
medicine and for the widespread use of quantitative angio-
graphic methods. Further DICOM developments will in-
clude standardized formats for physiological data such as
hemodynamic and electrocardiographic (ECG) waveforms
and patient record demographic and other information.
Other modalities such as other radiographic procedures and
intravascular ultrasound will eventually be incorporated into
the standard.
H. Radiation Safety
The use of ALARA—“as low as reasonably achievable”—
doses of X-ray radiation is important. Radiation exposure
may be expressed in terms of rems. Radiation injury is
defined by either stochastic effects (DNA injury) or nonsto-
chastic effects (cellular injury). The average background
radiation exposure is about 0.1 rem/year. Interventional
cardiologists receive another 0.004 to 0.016 rem/case. The
maximum recommended exposure by the National Council
on Radiation Protection and Measurement (NCRPM) is 5
rems/year for the total body. Over an individual’s lifetime,
the accumulated maximum dose should be no greater than
the accumulated rem exposure 3 age (or a maximum of 50
rems).
The risk of fatal cancer in the U.S. is about 20%. The
additional risk from radiation exposure in the cardiac
catheterization laboratory is about 0.04% 3 total cumulative
rem exposure. Pregnant workers can continue to work in the
cardiac catheterization laboratory if they so choose. Fetal
exposure, as measured by a waist dosimeter, should be no
more than 0.05 rem/month or ,0.5 rem for the entire
pregnancy.
Radiation exposure is measured by either X-ray film
badges or transluminescent dosimeter (TLD) badges. It is
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recommended that these badges be worn on both the
thyroid collar and under the lead apron at the waist. Ring
dosimeters are rarely worn in the cardiac catheterization
laboratory, even though hand exposure may be high.
X-ray scatter is reduced by minimizing the number of
magnified views, using digital-only cine runs, keeping the
image intensifier as close to the patient as possible, and
selecting the highest kilovolt level that provides acceptable
image contrast (to reduce the milliamperes generated). Most
of the radiation exposure during interventional procedures
comes from the extended use of fluoroscopy rather than the
brief cine runs. The closer the operator is to the X-ray tube,
the greater the radiation exposure (left anterior oblique
[LAO] cranial views may result in up to 6 times more
radiation than right anterior oblique [RAO] caudal views,
for instance). Proper collimation and shielding is important
to help reduce exposure. To minimize patient exposure to
scatter radiation, the same rules apply, with further efforts to
reduce the X-ray dose most important.
I. Special Concerns for the
Pediatric Catheterization Laboratory
The goals in the pediatric cardiac catheterization labora-
tory are to define internal cardiac and vascular structures and
hemodynamics. Shunts frequently require evaluation. In
recent years the pediatric catheterization laboratory has
become as much a therapeutic arena as a diagnostic one,
with atrial septostomy, valve and vessel dilation, and stent
implantation available. In some institutions, closure of
intracardiac defects such as patent ductus arteriosus or atrial
septal defect may be accomplished.
A pediatric cardiologist should be responsible for invasive
evaluation of patients from birth to 18 years of age. Adult
patients with congenital heart disease may be studied by a
pediatric cardiologist, a team of adult and pediatric cardi-
ologists working together, or an adult cardiologist with
specialized training and interest in adult congenital heart
disease. Complication rates in the pediatric cardiac cathe-
terization laboratory tend to be higher than those in adult
laboratories. Overall complications are about 8.8%, with
major complications about 2%. Neonatal patients and those
undergoing interventional procedures are at greatest risk.
Informed consent is usually obtained from parents or
guardians. Many diagnostic procedures can be done on an
outpatient basis, although this may not be practical for a
variety of reasons. Eligibility for early discharge after cardiac
catheterization must consider the child’s age and size,
patient or parent reliability, travel time and distance, dura-
tion of procedure, time of completion, cardiac physiology,
and loss of blood. Overnight observation is often required to
ensure safety.
Procedural issues in the pediatric laboratory include the
use of deep sedation and even general anesthesia. Vascular
access may be decidedly more challenging, although venous-
only catheterization may be performed when there is an
interatrial communication or by use of transseptal tech-
niques. Biplane angiography is also more important to help
visualize the cardiac structures adequately, to recognize
catheter positions, and to help reduce the total radiographic
contrast dosage. Heart rates in children are generally much
higher than in adults, requiring higher framing rates for
image acquisition (often 30 to 60 fps). Higher injection
rates (up to 40 mL/s) are also useful to help define abnormal
intracardiac anatomy.
The laboratory should perform a minimum of 75 pedi-
atric cases/year. Generally, an individual cardiologist should
perform at least 50 cases/year to maintain skills and reduce
risk of complications. A detailed QA plan should be
operative. The number of “normal” cardiac catheterizations
should be zero.
Oximetry rather than indocyanine green dye methods is
now used in shunt measurements. In pediatric cardiac
catheterization laboratories, specialized staff should be avail-
able to ensure familiarity with the procedures performed.
I. INTRODUCTION
A. Organization of Committee and Evidence Review
The Writing Committee consisted of acknowledged
experts in cardiac catheterization representing the ACC (9
members) and the SCA&I (2 members). Both the academic
and private practice sectors were represented. The docu-
ment was reviewed by 3 official reviewers nominated by the
ACC, the ACC Cardiac Catheterization and Intervention
Committee, the Diagnostic and Interventional Catheteriza-
tion Committee of the Council on Clinical Cardiology of
the AHA, the SCA&I, and 12 content reviewers nominated
by the Writing Committee. The document was approved for
publication by the ACC Board of Trustees and the SCA&I
Board of Trustees in April 2001 and endorsed by the AHA
and the Diagnostic and Interventional Catheterization Com-
mittee of the Council on Clinical Cardiology of the AHA.
This document will be considered current until the Task
Force on CECDs revises or withdraws it from distribution.
B. Purpose of This Expert Consensus Document
Cardiac catheterization settings and procedures have
evolved since publication of the ACC/AHA Guidelines for
Cardiac Catheterization and Cardiac Catheterization Lab-
oratories in 1991 (5). Whereas outpatient cardiac catheter-
izations were infrequent then, now almost all elective
diagnostic cardiac catheterizations are performed on an
outpatient basis. The setting for performance of cardiac
catheterizations has expanded to include not only traditional
medical centers with a cardiovascular surgical program, but
also community hospitals without cardiovascular surgical
backup and now some freestanding laboratories. The risks
associated with both diagnostic and interventional cardiac
catheterization have declined so markedly that older restric-
tions regarding the study of even higher-risk patients
deserve reassessment. Now it is rare to perform interven-
tional procedures with an empty operating room on standby
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and a surgical team on full alert. Indeed, the safety of such
interventional procedures is even being examined in hospital
settings without cardiovascular surgical facilities. The driv-
ing forces behind some of these changes have raised con-
cerns among the cardiology community, however, so the
time seems appropriate to evaluate these potential ethical
issues. Equipment is also rapidly evolving, especially in the
imaging arena. With the impetus provided by the universal
acceptance of the DICOM standards for cardiac angiogra-
phy, cinefilm is rapidly being replaced by compact discs and
computerized archiving systems. More changes, such as the
expanded use of the Internet, are imminent. Furthermore,
“ad-hoc” catheter revascularization is increasingly being
performed immediately following the diagnostic angio-
graphic procedure. The pediatric cardiac catheterization
suite is also evolving from a purely diagnostic laboratory to
an interventional laboratory.
II. THE EVOLUTION OF THE
CARDIAC CATHETERIZATION LABORATORY
Over the last half century, cardiac catheterization laborato-
ries have evolved from highly specialized research laborato-
ries into heavily used procedure rooms in which an extensive
array of diagnostic tests and therapeutic interventional
procedures are performed on millions of patients yearly.
Catheterization laboratories were first used to define the
hemodynamic features of complex congenital and acquired
valvular heart disease. The development of cardiopulmonary
bypass expanded the potential for surgical correction in
many of these patients. As surgical programs grew, cathe-
terization laboratories likewise proliferated.
With the advent of selective coronary angiography in the
late 1950s, physicians began to explore the possibility of
identifying and quantifying the extent of coronary artery
disease. Catheterization laboratories were few and largely
limited to major academic medical centers. By the late
1960s the use of aorto-coronary bypass surgery was quickly
expanding throughout the country, and the acceptance of
surgical revascularization promoted the proliferation of
cardiac catheterization laboratories. The decade of the
1970s was characterized by substantial improvements in
imaging systems and catheterization supplies and methods.
Preformed catheters, introduced by Drs. Judkins and Am-
platz, facilitated safe and expeditious catheterization from
the femoral route and rapidly became more popular than the
brachial approach pioneered by Dr. Mason Sones. Although
laboratories were disproportionately located in major med-
ical centers with cardiac surgical programs, the improved
safety and simplicity of diagnostic procedures fostered the
proliferation of diagnostic laboratories in community hos-
pitals in which cardiac surgery programs did not exist. These
hospitals retained close ties to tertiary centers where patients
could be easily referred or transferred for surgical proce-
dures. During this period the National Institutes of Health
funded several Myocardial Infarction Research Units (MI-
RUs) at select academic medical centers. It was in the
context of MIRU research that the safety of cardiac cathe-
terization in the setting of an acute myocardial infarction
(MI) was first demonstrated.
The late 1970s heralded a major change in the practice of
invasive cardiology. The introduction of intracoronary
thrombolysis and subsequently percutaneous transluminal
coronary angioplasty (PTCA) forever changed the character
of the catheterization laboratory. What was previously only
the setting for diagnostic testing became a therapeutic
laboratory where patients with both stable and unstable
coronary syndromes and valvular and congenital heart dis-
ease could be treated. The introduction of percutaneous
balloon valvuloplasty procedures in the mid and late 1980s
and advances in interventional procedures in the pediatric
catheterization laboratory further expanded the range of
therapeutic options. Because of the potential for cata-
strophic complications, especially with interventional pro-
cedures, these methods were appropriately confined to
laboratories with immediate surgical backup.
The last time the ACC/AHA Task Force on Practice
Guidelines developed a general document for cardiac cath-
eterization laboratories (5), the majority of the workload in
most laboratories consisted of diagnostic cardiac catheter-
ization procedures. Computerized recording methods and
digital angiography were considered research ventures, and
most cardiac catheterization procedures were performed on
inpatients. However, the use of balloon angioplasty was
rapidly increasing, and the 1990s heralded the evolution of
second-generation coronary therapeutic devices, including
several coronary atherectomy and laser catheters, followed
by the widespread use of coronary artery stents. Improve-
ments in the quality of imaging equipment, new potent
antiplatelet agents, and further improvements in coronary
stent technology resulted in a high degree of safety for most
interventional procedures. Furthermore, the majority of
routine diagnostic cardiac catheterizations performed
shifted to the outpatient setting.
Cardiac catheterization laboratories have further evolved
into multipurpose facilities. Improvements in X-ray systems
and the development of digital processing capabilities have
facilitated “noncardiac” vascular investigations and interven-
tions in other areas of the vascular system. At select centers,
in addition to cardiac disease, cardiologists are now involved
in the diagnosis and therapy of disease involving the
peripheral, renal, and carotid vasculature.
III. THE CARDIAC
CATHETERIZATION LABORATORY ENVIRONMENT
Although low, the risks from invasive cardiac procedures are
not zero. In addition to procedural-related complications,
occasional patients will become unstable during or after the
procedure. For this reason, other ancillary services (Table 1)
may be necessary to support the laboratory. At present,
there are three basic environments in which invasive cardiac
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procedures are performed: the in-hospital cardiac catheter-
ization laboratory with cardiac surgery capability, the in-
hospital laboratory without cardiac surgery capability in the
same hospital, and the freestanding laboratory. Certain
patient subgroups may be inappropriate for study in some of
these environments. The following outlines the current
laboratory environments and suggests patient populations
appropriate for study in each of these settings.
A. The Cardiac Catheterization Laboratory
at a Hospital With Cardiac Surgery Capability
The cardiac catheterization laboratory at a hospital with
cardiac surgery capability is the classical or traditional type
of cardiac catheterization laboratory facility. It is located at
a hospital that offers a broad range of cardiovascular services,
including cardiopulmonary bypass and coronary, cardiotho-
racic, and vascular surgery (i.e., full support services). The
presence of on-site cardiac surgery capability is the defining
service because it is unlikely that a cardiac surgical program
would exist in the absence of the other support services
listed in Table 1. If pediatric cardiac catheterization services
are provided, additional ancillary services are necessary, and
the availability of on-site pediatric cardiac surgery is essen-
tial if complex congenital heart diseases in infants and
children are to be studied and treated.
Fully trained personnel dedicated to the facility should
staff such a laboratory. This is the only setting in which
patients with poorly compensated heart failure, severe left
ventricular dysfunction (ejection fraction ,20%), acute
coronary syndromes, or other conditions that contribute to
clinical instability can be studied safely. Elective coronary
interventions are best performed in this setting. Physicians
should have appropriate credentials for performing both
diagnostic and interventional procedures or have ready
access to interventional cardiologists should an emergency
arise.
Although the majority of cardiac catheterization labora-
tories in this category are located within the main hospital
building, there may be special situations in which a mobile
laboratory is used temporarily at such a hospital or where a
laboratory may be in a different, but adjacent building
dedicated to outpatient services. Generally, these latter
situations may be considered similar to a laboratory with full
support services.
1. Patients Eligible for Invasive Cardiac Procedures at a
Hospital With Cardiac Surgery Capability. A hospital
with cardiac surgery capability provides an environment in
which all diagnostic and therapeutic procedures can be
performed on both stable and unstable patients, provided
the operators are physicians with appropriate experience,
adequate cumulative procedure volumes, and satisfactory
outcomes. Even though a hospital may have cardiac surgery
capability and is therefore technically eligible to provide
every type of invasive procedure, patients requiring less
commonly performed procedures (e.g., transseptal catheter-
ization and balloon valvuloplasty) or patients with more
complex conditions (e.g., adults and children with complex
congenital heart disease) may be better served by referral to
a more highly specialized center.
Performance of invasive cardiac procedures in the pedi-
atric and especially neonatal age groups requires knowledge
and skills that go beyond catheter manipulations and in-
clude the management of conscious sedation, administra-
tion of intravenous (IV) fluids, regulation of body temper-
ature, and the postprocedural care of infants and children.
These issues are important to understand, not only for the
physician, but also for nurses and other paramedical person-
nel who assist in the procedure. For these reasons, pediatric
procedures should only be performed if they are within the
competence of the operator and the experience of the team
supporting the physician in the invasive procedure. Pediatric
issues are summarized later in this document.
B. The Cardiac Catheterization Laboratory
at a Hospital Without Cardiac Surgery Capability
The performance of diagnostic cardiac catheterization in
facilities without the capability for on-site cardiac surgery is
now common in the U.S. About half of the 2,014 labora-
tories identified in 1996 had on-site cardiac surgery capa-
bility (6). The number of surgical programs has now
increased, and 72% of the 2,142 laboratories reported in
2001 have cardiac surgical programs on-site (1). Many
hospitals without cardiac surgery have permanent, in-house
cardiac catheterization laboratories and provide the majority
of supporting services except for cardiac surgery. Although
cardiac surgery is the defining service, the importance of the
other services listed in Table 1 cannot be overemphasized.
This is especially true in situations in which a mobile cardiac
catheterization laboratory operates at a smaller rural hospi-
tal. In this setting, support services such as vascular surgery
and comprehensive imaging techniques may not be available
should important complications develop. It is mandatory
that catheterization laboratories operating in this setting
have well-defined selection and exclusion criteria and pro-
vision for identification of emergency situations requiring
Table 1. Optimal On-Site Support Services for Invasive
Cardiac Procedures
For Adult Invasive Procedures
Adult cardiovascular surgery
Adult Coronary and Intensive Care Units
Vascular surgery
Adult nephrology consultation and dialysis
Adult neurology consultation
Hematology consultation and blood bank services
Imaging services (computed tomography [CT] and magnetic
resonance imaging [MRI], ultrasound)
For Pediatric Invasive Procedures
Pediatric cardiovascular surgery
Pediatric intensive care unit
Pediatric anesthesia
Pediatric neurology consultation
Pediatric nephrology consultation and dialysis
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immediate transfer to a tertiary facility and insertion of an
intra-aortic balloon pump. Written agreements should be
signed with a tertiary center for the timely (,60 min)
transfer and acceptance of patients in the event of a crisis. In
some settings, a physician using a mobile laboratory may live
in the local community and is available after the laboratory
leaves to assess complications or assist in patient manage-
ment. In other situations, however, the physician perform-
ing the procedure may live in a distant area and may leave
the hospital after the procedure. In this latter circumstance,
it is essential that local physicians and support staff have an
understanding of the potential complications of cardiac cath-
eterization and be an integral part of the management process.
It is possible for catheterization laboratories to function
with high quality and safety in hospitals without a cardiac
surgical program; however, services are necessarily limited.
To further ensure safety, a formal arrangement between
the laboratory and a nearby institution with cardiac surgical
services must be made. Regulatory authorities and third-
party reimbursement agencies should demand formal doc-
umentation and periodic review of such arrangements.
1. Patients Eligible for Diagnostic Cardiac Catheteriza-
tion at a Hospital Without Cardiac Surgery Capability.
Patients undergoing invasive procedures in this type of
facility require a higher level of screening to avoid situations
that might require urgent cardiac surgery or result in a
complication that could not be managed effectively with the
inherent delays encountered during transfer to another
facility. Clinically, adults at the greatest risk include the very
elderly (.75 years of age), those with New York Heart
Association (NYHA) functional class III or IV congestive
heart failure, those with acute coronary syndromes or recent
MI, and those in whom noninvasive testing demonstrates
severe ischemia. Patients with suspected or known left main
disease, markedly reduced left ventricular function (ejection
fraction ,20%), or severe valvular dysfunction, especially in
association with poor left ventricular performance, are also
at increased risk. Patients at increased risk for vascular
complications should not be studied in facilities without the
capability to diagnose and surgically treat such complica-
tions should they arise. Such patients include those with
known severe peripheral vascular disease, severe systolic hyper-
tension, a bleeding diathesis, the need for continuous antico-
agulant therapy, or severe obesity. Pediatric patients should not
be studied. Patients receiving dialysis who may decompensate
after the procedure are generally best studied at a facility with
rapid access to a dialysis center.
It is not feasible to list every possible situation that could
develop, but general exclusions for the performance of
invasive cardiac procedures at hospitals without cardiac
surgery are summarized in Table 2. It is important to
emphasize that these recommendations are based on the
literature and the judgment and experience of Committee
members rather than extensive clinical evidence developed
from outcome measures.
2. Patients Eligible for Therapeutic Invasive Procedures
at a Hospital Without Cardiac Surgery Capability.
Therapeutic invasive procedures primarily consist of valvu-
loplasty, pericardiocentesis for tamponade, and PCIs, as
well as certain procedures specific for the pediatric and adult
congenital heart disease populations. In evaluating the use
of these procedures at hospitals without cardiac surgery
capability, it is important to consider the clinical situation
for which the procedure is needed, and specifically whether
it is an emergency or elective procedure. Valvuloplasty is not
required on an emergency basis, and therefore it should not
be performed at hospitals without full support services,
including cardiac surgery. Moreover, because it requires a
Table 2. General Exclusion Criteria for Invasive Cardiac Procedures in Settings Without Cardiac Surgery
Type of
Patient Diagnostic Procedures Therapeutic Procedures
Hospital Adult c Age .75 years c All valvuloplasty procedures
c NYHA Class III or IV heart failure c Diagnostic pericardiocentesis when the
effusion is small or moderate in size and
there is no tamponade
c Acute, intermediate or high-risk ischemic syndromes
c Recent MI with post-infarction ischemia
c Pulmonary edema thought to be caused by ischemia c Elective coronary interventions
c Markedly abnormal noninvasive test indicating a high likelihood
of left main or severe multivessel coronary disease
c Therapeutic procedures in adult congenital
heart disease
c Known left main coronary artery disease
c Severe valvular dysfunction, especially in the setting of depressed
left ventricular performance
c Patients at increased risk for vascular complications
c Complex adult congenital heart disease
Pediatric c No procedures approved c No therapeutic procedures approved
Freestanding
Laboratory
Adult c All of the above plus c No therapeutic procedures approved
c Patients at high risk due to the presence of comorbid
conditions, including the need for anticoagulation therapy,
poorly controlled hypertension or diabetes, contrast allergy, or
renal insufficiency
Pediatric c No procedures approved c No therapeutic procedures approved
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unique knowledge base, special equipment, and technical
expertise, it is advisable to refer the patient to a regional
center with experience in this technique.
In the setting of pericardial tamponade, pericardiocentesis
can be a lifesaving therapeutic procedure, and the potential
benefits of the procedure far outweigh the risks. Although
commonly performed in catheterization laboratories as a mat-
ter of convenience, ECG- or echocardiographic-guided peri-
cardiocentesis can be performed in other areas of the
hospital. In the setting of tamponade, therefore, pericardio-
centesis should be immediately available, irrespective of the
hospital status. In the absence of tamponade, diagnostic
pericardiocentesis only rarely provides critical clinical infor-
mation but can be performed with minimal risk of ventric-
ular puncture or coronary laceration if the pericardial effu-
sion is sizeable. Therefore, assuming that the operator is
skilled and experienced, elective pericardiocentesis for large
effusions is acceptable in hospitals without immediate car-
diac surgery capability. Elective procedures in patients with
moderate or small pericardial effusions are better performed
at hospitals in which immediate cardiac surgery is available
should ventricular perforation or coronary laceration occur.
The performance of coronary angioplasty and other PCIs
at hospitals without immediate surgical backup is contro-
versial. In simple terms, patients can be divided into two
groups: 1) those having the procedure as an alternative to
thrombolytic therapy within 12 h from the onset of acute
MI and 2) all others who are assumed to be undergoing
elective or semielective procedures. In the setting of an acute
MI, several small studies (7–9) have suggested that patients
presenting to hospitals without cardiac surgery capability
can be treated with primary angioplasty without a measur-
able difference in complications or outcomes when com-
pared with hospitals with on-site cardiac surgery capability.
However, these are not randomized trials, and none of these
studies are of sufficient size to detect a small difference
between groups. Recently reported data from the National
Registry of Myocardial Infarction Investigators have re-
vealed 28% less mortality among patients undergoing pri-
mary angioplasty in high-volume hospitals than in those
undergoing the procedure in low-volume settings (4). Most
hospitals without cardiac surgery capability perform a rela-
tively low volume of cardiac interventions.
Although some studies support the use of primary angio-
plasty at hospitals without on-site cardiac surgery capability,
important operator, laboratory, and institutional require-
ments must exist (9). If it is accepted that it is possible to
develop a program of primary angioplasty for MI at a
hospital without on-site cardiac surgery capability, the
important question still remains whether this is an appro-
priate decision based on a desire to provide the best possible
care for the local community. For example, is it really
necessary to offer primary angioplasty at a hospital without
cardiac surgery capability if a hospital with a cardiac surgical
program is ,10 min away? Although it can be argued that
should an interventional complication occur, transport time
and delay to a surgical center would be inconsequential, it is
also appropriate to make certain that the motives for
offering this service at a hospital without on-site cardiac
surgery capability are not based purely on financial consid-
erations or physician convenience. Moreover, it is unlikely
that smaller hospitals performing only emergency proce-
dures on patients with acute MI can satisfy the procedure
volume requirements that now are associated with better
outcomes (3,4).
In the final analysis, this Committee endorses the opin-
ions and recommendations of the current ACC/AHA
Committee revising the 1993 PTCA guidelines (3). In
brief, primary angioplasty for reperfusion therapy in the
setting of acute myocardial infarction in hospitals without
onsite cardiac surgery capability must only be performed in
a setting where there is a proven plan for rapid access
(within 1 h) to a cardiac surgery operating room in a nearby
facility with appropriate hemodynamic support capability
for transfer. The procedure should be limited to patients
with ST-segment elevation MI or new LBBB on ECG, and
done in a timely manner (balloon inflation within 90 6
30 min of admission) by persons skilled in the procedure
(those performing $75 PCIs/year) and only at facilities
performing a minimum of 36 primary PCIs/ year (3). Newer
thrombolytic regimens, especially those combining throm-
bolytic agents with glycoprotein (GP) IIb/IIIa inhibitors,
have higher reperfusion rates approaching those achieved by
mechanical means and could reduce this as an issue (10,11).
Although the need for swift intervention drives the
argument for primary coronary intervention at hospitals
without on-site cardiac surgery capability, this does not
apply to elective coronary intervention. The risks of coro-
nary intervention have diminished with the increased use of
coronary artery stents and GP IIb/IIIa inhibitors. Never-
theless, complications that require urgent bypass surgery still
occur, and there will always be some risk related to the
transfer between hospitals of patients for whom an inter-
ventional procedure has failed. These risks, however small,
must be balanced against the proven safety of performing
the procedure at a hospital with on-site cardiac surgery
capability. The performance of elective angioplasty in hos-
pitals without such capability has been reported from several
centers outside the U.S. (12,13) where cardiac surgery is
generally less available. However, given the availability of
cardiac surgery in the U.S., it seems quite unlikely that
patients or their families are significantly inconvenienced by
referral to a hospital with on-site cardiac surgery available.
Therefore, in agreement with the upcoming ACC/AHA
PCI guidelines (3), it is the opinion of this Committee that
the performance of elective coronary interventions in hos-
pitals without on-site cardiac surgery capability cannot be
endorsed at this time. The Committee is aware that certain
programs that do perform interventions in this setting are
affiliated with a high-volume PCI/coronary artery bypass
graft (CABG) center and have a well-organized plan for
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emergency transfer of patients, a sophisticated communica-
tion system between the primary site and the tertiary center,
and a means for measuring and reporting patient compli-
cations and outcomes. Such a strictly monitored and con-
trolled setting may allow for elective interventional proce-
dures without cardiac surgical backup on-site, but outcomes
from such programs have yet to be reported. This is
obviously a dynamic area that awaits further data regarding
the safety and outcomes of patients treated.
In addition, the desire for an interventional cardiac
catheterization program should not be used to justify the
development of a low-volume cardiac surgery program.
There is concern among Committee members that low-
volume cardiac surgery programs may be developed for the
sole purpose of allowing an interventional cardiac catheter-
ization program to be operative. The development of a
cardiac surgery program should reflect the need based on a
high volume of cardiac catheterization procedures.
C. Cardiac Catheterization and
Diagnostic Procedures in the Freestanding Laboratory
A freestanding laboratory is not physically attached to a
hospital. By definition, it is a laboratory in which quick
transportation of a patient to a hospital by gurney is not
possible. Although some hospitals build such laboratories
adjacent to their primary facility, many are privately owned,
and the physicians who use the facility may also own it. In
the 2001 Directory of Cardiac Catheterization Laboratories
assembled by the SCA&I, 58 such laboratories submitted
data (1), but this number is clearly increasing. It is the
responsibility of each freestanding laboratory to have a
formal relationship with at least 1 tertiary referral hospital so
that a written established plan for the emergency transfer of
patients is in place. Furthermore, freestanding facilities
must have the necessary equipment for intubation and
ventilatory support. Physicians using these facilities must be
capable of performing endotracheal intubation and inserting
an intra-aortic balloon pump. Appropriate QA and ongoing
QI programs must be established in writing and docu-
mented. Oversight has traditionally been provided by a
tertiary referral hospital, but alternatives that comply with
the maintenance of the highest concern for patient care may
be used if acceptable by local standards and if a well-defined
QA program is operative.
1. Patients Eligible for Cardiac Catheterization in a
Freestanding Laboratory. Patients undergoing cardiac
catheterization procedures in a freestanding facility require
the highest level of screening to avoid situations that might
require urgent cardiac surgery or result in a complication for
which time spent transferring the patient to a hospital could
be detrimental. All of the exclusions that apply to cardiac
catheterization laboratories at hospitals without full-support
services also apply to freestanding laboratories. Other pa-
tients who should not be studied in a freestanding facility
include those with cardiac or comorbid conditions of such
severity that the patient’s condition could potentially be-
come unstable during or after the procedure (Table 2).
2. The Mobile Cardiac Catheterization Laboratory. The
mobile cardiac catheterization laboratory may be located at
a hospital with cardiac surgical backup, at a hospital without
cardiac surgery capability, or even in a freestanding envi-
ronment. These laboratories are subject to the same con-
cerns and quality controls as those of any laboratory in the
respective setting. Mobile laboratories are occasionally used
as temporary facilities before completion of a fixed (perma-
nent) laboratory. To be eligible for study in the mobile
laboratory, patients must meet the same criteria as those for
more traditional environments.
D. Candidates for Same-Day
or Ambulatory Cardiac Catheterization
Improvements in the safety and ease of performing
invasive cardiac procedures plus the constant pressure to
minimize costs have made it quite uncommon to hospitalize
patients for only an invasive cardiac procedure. Indeed, for
the vast majority of adult patients, a diagnostic procedure
can be safely completed in an ambulatory setting. Patients
should be hospitalized if their clinical condition warrants it,
after which an invasive cardiac procedure may then become
part of their overall management. In some isolated situa-
tions, preprocedure hospitalization is still appropriate. For
example, patients who require continuous anticoagulation
therapy may require hospitalization to switch safely from
warfarin to heparin anticoagulation. Patients with renal
insufficiency benefit from preprocedural hydration or drugs
to help reduce contrast nephropathy. Patients with brittle
diabetes who also require steroids to reduce the risk of
contrast-allergic reactions may require prehospitalization.
Preprocedural admission may also be appropriate for other
situations, and the decision of the individual practitioner
should be respected when it is in the best interest of the
patient.
Noninvasive testing can often identify patients with
high-risk coronary or valvular disease before catheterization
and is helpful for identifying patients who should not be
studied in settings without cardiac surgery capability. How-
ever, diagnostic studies of high-risk patients may still be
initiated in the outpatient setting before referral to the
appropriate settings. If, as suspected from noninvasive
testing, the catheterization study confirms a high-risk ana-
tomic situation, admission to the hospital may become
necessary after the procedure.
Because of the overall safety of diagnostic procedures,
patients are often discharged within 2 to 6 h of completion
of the study. This applies not only to outpatients, but also to
inpatients for whom a disposition is made rapidly after
completion of the procedure. A general scheme for the
disposition of patients after diagnostic catheterization is
shown in Figure 1. Rarely, a patient will develop a
procedure-related complication that requires hospitaliza-
tion. More patients will require admission because of the
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findings from the procedure. A patient who develops a large
hematoma may require a more prolonged period of bed rest
and observation to ensure that the puncture site has stabi-
lized. Patients who are found to have important left main
disease should be considered for admission pending early
surgical therapy or at least until it is clear that the diagnostic
procedure has not caused clinical instability. Finally, some
patients may require observation overnight simply because
they do not have a supervised home setting. Table 3 lists
possible situations for which early (,2 to 6 h) discharge
after diagnostic catheterization may be unwise. These are
not meant as absolute exclusion criteria prohibiting early
discharge, but the practitioner should consider hospitaliza-
tion when treating such patients. Based on the judgment of
the physician, it would be appropriate to observe patients
with 1 or more of these clinical risks for a longer period of
time.
Because of the improving safety of coronary interventions
and newer access techniques, such as the radial approach as
well as the availability of vascular closure devices, outpatient
coronary intervention may become a reality. This concept is
currently being investigated. At this time it is not approved
by the Committee.
Because of the simplicity and safety of diagnostic cathe-
terization, the vast majority of patients can be discharged
home within 2 to 6 h. This applies to inpatients as well as
outpatients. For example, a patient may be admitted for
evaluation of a prolonged episode of chest pain, but subse-
quent testing shows no evidence of MI. In some patients, it
may be appropriate to consider coronary angiography as the
first diagnostic test. If coronary angiography shows no
evidence of coronary disease, the patient may be discharged
2 to 6 h after the procedure to complete evaluation as an
outpatient. Patients undergoing radial artery cardiac cathe-
terization may be discharged as early as 90 min after the
procedure.
There are three basic steps in determining the appropri-
ateness of early discharge for patients. First, a patient may
require a prolonged stay if an important complication has
occurred. Second, the procedure may reveal new findings for
which hospitalization is indicated. Finally, appropriate care of
the patient for noncardiac issues may be necessary for safety.
Figure 1. General scheme for the disposition of adult patients after
diagnostic cardiac catheterization
Table 3. Suggested General Exclusion Criteria for Early (,2–6 h) Discharge after Invasive Cardiac Procedures
Type of
Patient Diagnostic Procedures Therapeutic Procedures
Adult c High risk due to identification of left main disease c All procedures are excluded at this time, but the early discharge of
selected patients after coronary intervention is under investigation
(i.e., patients with radial artery access or after the use of
percutaneous closure devices)
c NYHA Class III or IV heart failure
c Unstable ischemic symptoms at any time after the procedure
c Recent MI with post-infarction ischemia
c Pulmonary edema thought to be caused by ischemia
c Severe aortic stenosis with LV dysfunction
c Severe aortic insufficiency with a pulse pressure
.80 mm Hg
c Poorly controlled systemic hypertension
c Inadequate or unreliable follow-up over the next 24 h
c Generalized debility or dementia
c Renal insufficiency (creatinine .1.8 mg/dl)
c Need for continuous anticoagulation therapy or treatment of
a bleeding diathesis
c Large hematoma or vascular complication
Pediatric c Young age (#5 years of age) c All procedures excluded
c Complex congenital heart disease
c Any condition resulting in important cyanosis
c Most cases requiring a large arterial sheath
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IV. QA ISSUES IN THE
CARDIAC CATHETERIZATION LABORATORY
The modern cardiac catheterization laboratory is an amal-
gamation of complex, highly sophisticated medical and
radiological instrumentation used in the diagnosis and
management of patients with not only chronic stable dis-
ease, but also acute life-threatening illnesses. In any com-
plex, procedure-oriented area, it is necessary to have a
well-organized program of QA that focuses on individual
and laboratory outcomes. In addition, a continuous program
of quality improvement (QI) should be implemented to
provide ongoing feedback and structure for change. The
following discussion summarizes the key components of a
QA program for both diagnostic and interventional cardiac
catheterization laboratories. These components are: 1) clin-
ical proficiency, 2) equipment maintenance and manage-
ment, and 3) a QI process. A fourth component, radiation
safety, is discussed separately later in this document.
A. Clinical Proficiency
The assessment of clinical proficiency in the catheteriza-
tion laboratory is based on a composite of cognitive skills,
procedural conduct, and clinical judgment. A deficiency in
any one element is enough to worsen clinical outcomes;
thus, all elements must be considered. Unfortunately, there
is no unique source that details “how to do things correctly.”
Although clinical experience is the sine qua non of profi-
ciency, the myriad of techniques and technology preclude
rigid delineation of a singular “right way.” There is, how-
ever, one incontrovertible bottom line—patient outcomes.
1. Patient Outcomes in the Diagnostic Cardiac Cathe-
terization Laboratory. a. RATES OF “NORMAL” CARDIAC
CATHETERIZATIONS. The frequency of normal hemody-
namic and angiographic findings at diagnostic catheteriza-
tion is a function of the pretest likelihood of disease and the
physician’s clinical acumen. For purposes of definition,
“normal” coronaries are defined as those with no or physi-
ologically insignificant diameter stenosis by visual inspection
in patients studied specifically to assess coronary anatomy.
Few contemporaneous sources of data give an acceptable
percentage of normal cases. Administrative databases gen-
erally lack the requisite clinical information, whereas most
clinical databases fail to include such preprocedural data as
preopertive (procedure) diagnosis and appropriate ancillary
diagnostic data. In an exhaustive, although now dated,
review of coronary arteriography, the RAND Corporation
study group found rates of normal diagnostic cardiac cath-
eterization studies ranging from 9% to 36% (average, 21%)
(14). These data must be viewed circumspectly, given the
relatively unsophisticated X-ray imaging systems in use at
that time, the variable criteria for “normal,” and the differing
pretest likelihood of finding significant disease. In the
Coronary Artery Surgery Study (CASS) Registry (15), the
rate of normal arteriograms was 19%, although the appro-
priateness of extrapolating these data to the present is also
questionable. More recent data from the SCA&I indicate
that the frequency of normal angiograms is 20% to 27%,
which appears to vary little over a reporting period of several
years (16,17).
It is recognized that many cardiac catheterization studies
include patients with insignificant disease (,50% coronary
diameter narrowing by visual estimate). Among those con-
sidered “normal” it is evident that many patients may have
significant coronary plaque burden before the coronary
lumen is obviously reduced. Clearly many acute coronary
syndromes occur in patients without significant luminal
narrowing. In addition, certain clinical syndromes may
relate to coronary endothelial dysfunction. Some laborato-
ries may also have a high prevalence of patients studied for
non-coronary issues, such as pulmonary hypertension, car-
diomyopathy, valvular disease, or adult congenital heart
disease. These issues should be taken into account when
assessing the rate of “normal” cardiac catheterization pro-
cedures performed by any facility.
The vast majority of reported data refer to coronary artery
disease. It is of interest to note that no data are reported for
evaluation of hemodynamic problems. This may reflect the
proliferation of noninvasive modalities as an integral part of
the cardiologic evaluation of patients with suspected valvular
or myocardial disease. Nevertheless, there are occasions
when cardiac catheterization is recommended to clarify
uncertainties related to valvular disease or ventricular func-
tion that remain after noninvasive assessment.
b. COMPLICATION RATES DURING DIAGNOSTIC CATHETER-
IZATION. There is extensive literature on the major com-
plications of diagnostic cardiac catheterization (18). Fortu-
nately, the (composite) rate of major complications is
“acceptably” low at 1% to 2% (Table 4). As expected, the
likelihood of major complications increases significantly
with the severity of the underlying cardiac and noncardiac
disease (19). Patients with both valvular and coronary artery
disease are slightly more likely to sustain a complication
than patients with isolated coronary artery disease (20).
Although complications encountered in patients with val-
vular or myocardial disease are more likely to reflect the
patient’s underlying clinical status, specific complication
Table 4. Complication Rates (%) During Diagnostic Cardiac Catheterization: Results from the
SCA&I Registry (18)
Year(s) Death MI Neurological Arrhythmia Vascular Contrast Other Total
1979–1982 0.14 0.07 0.07 0.56 0.57 — 0.41 1.82
1984–1987 0.10 0.06 0.07 0.46 0.46 0.23 0.28 1.74
1990 0.08 0.03 0.06 0.33 0.40 0.37 0.48 1.77
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rates for transseptal catheterization (21) and endomyocar-
dial biopsy (22) have been reported and fall within the range
referenced earlier. Because of patient selection, the likeli-
hood of complications during outpatient studies is less than
that found during inpatient examinations (19), although the
constantly changing definition of “outpatient” may blur this
distinction. It must be acknowledged that at present, dy-
namic changes are occurring in the choice of access site for
procedures, the caliber of diagnostic catheters, and the
means of achieving access site hemostasis. How these
variables will change complication rates is unknown, al-
though it is unlikely that any alternative access sites or
vascular occlusion devices will significantly affect the already
low major complication rate.
c. DIAGNOSTIC ACCURACY AND ADEQUACY. An important,
although generally ignored area, is that of the completeness
and diagnostic accuracy of catheterization procedures. In-
complete or aborted procedures, technically inadequate
procedures that fail to obtain the critical information for
diagnostic purposes, and erroneous interpretation of the
acquired information are markers of quality no less impor-
tant than the previous 2 areas. Failure to engage coronary
arteries selectively often results in insufficient opacification
of the artery to accurately assess stenosis. Failure to identify
or engage all bypass grafts selectively is frequently another
reason that angiograms are incomplete and need to be
repeated. Inability to recognize the presence of coronary
arteries with anomalous origins also contributes to this
problem. Understandably, there is an absence of literature
on this subject. The implications of inadequate or incom-
plete studies are significant and range from the need to
perform repeat procedures to obtain the key information to
performance of unnecessary and more invasive procedures.
In the PCI era, the need for high-quality angiography is
great. Inadequate attention to the details of accurate hemo-
dynamic recording in patients with valvular heart disease
and the failure to accurately demonstrate coronary anatomy
must be viewed as important measures of outcome. It seems
clear that inadequate diagnostic procedures as defined ear-
lier should occur in far fewer than 1% of cases.
d. THE SPECIAL CASE OF THE “AD HOC” PCI. The perfor-
mance of a coronary interventional procedure at the con-
clusion of the diagnostic session presents several important
issues for assessment of quality. Complications engendered
during diagnostic catheterization and angiography, e.g.,
coronary dissection or abrupt occlusion, may well be treated
with prompt intervention. Does the success of the interven-
tion mitigate the inciting event? Although the composite
procedure was “successful,” how is the original complication
recorded? The majority of such “ad hoc” procedures are
currently performed as the result of efforts to improve
cost-efficiency as well as patient convenience and satisfac-
tion. The ad hoc procedure also facilitates the management
of patients with both stable and unstable coronary syn-
dromes. In these cases, complications encountered during
the interventional portion of the procedure should be
attributed to the interventional procedure and not to the
antecedent diagnostic study. Given the increasing use of the
hybrid approach, it will be important to carefully define its
indications, clinical outcomes, and overall cost effectiveness.
2. Patient Outcomes in the Interventional Cardiac Cath-
eterization Laboratory. Although patient outcomes are
clearly the most important indicators of proficiency and
competency in interventional cardiology (2), they are argu-
ably the most difficult to quantify accurately. The impor-
tance of risk-adjustment of crude event frequencies cannot
be overstated (35). Therefore, it is essential that careful and
complete preprocedural and intraprocedural information be
reliably collected, sorted, and analyzed. Given that operator
and institutional outcomes depend on many demographic,
clinical, anatomic, and administrative variables, an adequate
information system within the laboratory is mandatory.
Without a complete recording of such variables, meaningful
analysis of event rates is impossible. It is very difficult to
risk-adjust variables for low-volume operators based on the
wide confidence intervals for outcomes in this situation.
Given this caveat, the emphasis on individual and insti-
tutional outcomes is appropriate (2). Operators must be
responsible for their actions and resulting consequences.
The ability to estimate the likelihood of significant compli-
cation (36,37), choose devices and conduct procedures
appropriately (38), promptly recognize and treat ischemic
complications (39), select cases appropriately, and be able to
say “no” are hallmarks of an experienced, competent oper-
ator. It is the responsibility of the director of the cardiac
catheterization laboratory to establish a method of QA to
track major events, (e.g., death and serious hemodynamic
and/or arrhythmic events). In addition, periodic review of
less severe complications (e.g., hematoma or pseudoaneu-
rysm rates) should be part of any ongoing QI program.
Admittedly, many outcomes are hard to measure, but there
is little ambiguity when outcomes for PCI are either
consistently superior (e.g., ,2% major complication rate) or
consistently suboptimal (e.g., .5% major complication
rate). At present, with overall in-hospital mortality averag-
ing 2% and rates of emergent CABG averaging ,1%, a
major complication rate #3% (95% CI 1.9%, 4.1%) is to be
expected.
Table 5 summarizes in-hospital outcomes from recently
published data on this subject. Each series includes patients
undergoing PCI for a variety of indications, e.g., stable
angina, post-infarct angina, and acute MI. The definitions
of “elective,” “urgent,” and “emergent” vary among studies.
Complication rates (especially bleeding and access site
complications) in the GP IIb/IIIa inhibitor era not only vary
according to the definition applied, but almost universally
reflect the clinical trial literature. Complication rates in
community-based practice must await the development of
an appropriate data collection instrument. The use of
30-day event rates to benchmark operator performance has
been advocated by some (40).
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Table 6 summarizes representative outcomes from the
published literature on PCI for acute MI. Here, too, event
rates are unadjusted, and rates of access site and bleeding
complications reflect a complex mix of systemic anticoagu-
lation, systemic lytic activity, and the adjunctive use of
platelet antagonists. These issues are particularly critical in
the interpretation of central nervous system complications
during PCI in this setting.
Although the frequencies of adverse events are likely to
change over time as the result of continuing improvements
in technology, clinical competence and its assessment will
remain the foundation on which a QI program rests. Table
7 summarizes current approaches to the assessment of
proficiency in coronary intervention for both individuals and
institutions.
B. Equipment Maintenance and Management
The modern diagnostic and interventional catheterization
laboratory uses many sophisticated radiological, electronic,
and computer-based systems, which require a program of
rigorous maintenance and troubleshooting. The X-ray im-
aging system, a crucial component of every laboratory, must
be carefully assessed at frequent intervals to detect early
signs of deterioration in performance. Unfortunately, this
aspect of quality control is the first to be sacrificed in an era
of cost cutting.
A program of periodic assessment of system performance
and (cine) image quality has been recommended by the
SCA&I (41). Additional programs, which will address
issues specific to digital imaging systems, are under evalua-
tion (41). A representative outline of the performance
characteristics needed to assess radiographic cardiac imaging
systems is presented in Table 8.
Note that at present the only federally mandated param-
eter of image performance is the maximum table-top
exposure rate (10 R/min) for conventional cardiac fluoros-
copy. The concept of minimum performance standards
must await universal acceptance of a suitable test instrument
for cardiac fluoroscopy. There is considerable heterogeneity
across laboratories in selective measurements of image
quality (42). Such heterogeneity precludes specific recom-
mendations with respect to what is considered “acceptable”
performance. Current-generation imaging systems must be
capable at minimum of providing images of sufficient
diagnostic quality to enable decision making with respect to
intervention and provide sufficient spatial and contrast
resolution for the conduct of contemporary coronary inter-
vention.
Interventional procedures occur in environments of high
information density. In the past, physiological recorders
were used only for the acquisition and recording of analog
signals. They are now required to serve as front ends for the
increasingly complex gathering of data. These recorders
have essentially been transformed into desktop personal
computers capable of acquiring, storing, and transmitting
data to other sites. Given the critical importance of these
Table 5. Major In-Hospital Complication Rates (%) Related to Contemporary PCIs
Study Year Reference Death Q-Wave MI
Emergency
CABG Neurological
Major
Vascular
NHLBI-DR 2000 (23) 1.9 2.8 0.4 0.3 3.8
SCA&I 2000 (24) 0.5 N/A 0.5 0.1 0.2
BARI 1996 (25) 0.7 2.8 4.1 0.2 0.2
NY State* (Balloon) 1997 (26) 0.85 N/A 2.7 N/A N/A
NY State* (Stent) 1997 (26) 0.71 N/A 1.66 N/A N/A
Northern New England 1996 (27) 1.2 2.0 1.3 N/A N/A
Medicare 1997 (28) 2.5 N/A 3.3 N/A N/A
EPILOG† (Abciximab) 1997 (29) 0.3 0.4 0.4 0.2 1.1
EPILOG† (Placebo) 1997 (29) 0.8 0.8 1.7 0.0 1.1
EPISTENT† (Abciximab) 1998 (30) 0.3 0.9 0.8 0.4 2.9
EPISTENT† (Placebo) 1996 (30) 0.6 1.4 1.1 0.1 1.7
*Overall risk-adjusted rates; †30-day event rate; N/A 5 data not available.
Table 6. Major Complication Rates (%) Related to PCI for Myocardial Infarction
Study Year Reference Death
Emergent
CABG Neurological Vascular*
RAPPORT† (Placebo) 1998 (31) 1.7 5.4 0.0 3.7‡/9.5‡
RAPPORT† (Therapeutic) 1998 (31) 1.2 1.2 0.0 12.0‡/16.6‡
PAMI§ (PTCA/tPA) 1993 (32) 2.6 N/A 0.0 2.1
PAMI§ (tPA) 1993 (32) 6.5 N/A 3.5 0.5
PAMI* (Stent) 1999 (33) 3.5 N/A 0.2 5.1
PAMI* (No stent) 1999 (33) 1.8 N/A 0.2 3.8
GUSTO IIB* (PTCA) 1997 (34) 5.7 N/A 1.1 12.3
GUSTO IIB* (tPA) 1997 (34) 7.0 N/A 1.9 9.5
*Vascular, including bleeding unless noted; †RAPPORT data are 7-day event rates; ‡Vascular only; §Bleeding only.
RAPPORT data are 7-day event rates; PAMI data are in-hospital event rates for PTCA or tPA and 30-day event rates for
stent/no stent; GUSTO IIB data are 30-day event rates.
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data for numerous purposes (e.g., billing, QA, report
generation), flawless and lossless transmission must take
place all the time. Backup systems and low-cost storage
media are essential.
The need for patient safety–related precautions is self-
evident. The operational efficiency of infrequently used
equipment (e.g., defibrillators) must be tested routinely and
appropriate logs kept. Electrical isolation and grounding
systems must be regularly assessed. The number of ancillary
devices used in coronary intervention (e.g., Doppler and
pressure-tipped sensor wires and ultrasound catheters) now
requires that electrical safety precautions that were adequate
in the past (43) be revisited.
C. QI Program Development
A continuous QI program with regard to clinical profi-
ciency must function under the broad rubric of system-level
performance analyses, which should connote a more con-
structive (rather than punitive) context (38). Table 9 out-
lines some of the essential elements of such a program.
An overall continuous QI program is only as effective as
the commitment of all involved in the process of healthcare
delivery. Clearly, the most conspicuous components are
procedural outcome and individual operator proficiency.
Thus, the emphasis and direction in the profession alluded
to earlier, in which sub-subspecialty “boards” in interven-
Table 7. Assessment of Proficiency in Coronary Intervention
Type Component Mode of Assessment
Individual Cognitive c Formal training program
c Present requirement by ABIM for CVD: 3-year fellowship in
ACGME-accredited program
c Board certification: Requirement for added qualification in
interventional cardiology: 12 months in ACGME-accredited
program and pass grade on ABIM examination (“Board”) for
interventional cardiology. As of 2003, only candidates who have
successfully completed the 12-month fellowship will be allowed to
sit for the examination. Before 2003, “practice pathway” possible
(150 cases over 2 years or 500 since training).
Procedural c Recommended average procedural volume: $75 cases/year
c Risk-adjusted outcomes
c Individual data benchmarked against the ACC NCDR™ or similar
database
Judgment c Board certification
c Peer recognition
Laboratory Procedural outcomes c Risk-adjusted outcomes
c Comparison with similar institutions
c Laboratory data benchmarked against national databases such as the
ACC NCDR™
Activity c Minimum performance of 200 interventions/year; ideally, a
minimum of 400 interventions/year
Oversight c Director with career performance of .500 invasive cases and board
certification in interventional cardiology
c Establishment of a mentoring program for operators who perform
,75 procedures/year by those who perform .150 procedures/year
Support c QA staffing to monitor complications and outcomes
c Experienced support staff to handle emergencies
c Facilities and equipment for high-resolution fluoroscopy and digital
video processing
ABIM 5 American Board of Internal Medicine; ACGME 5 Accreditation Council of Graduate Medical Education;
NCDR™ 5 National Cardiovascular Data Registry™.
Table 8. Performance Characteristics of Radiographic
Imaging Systems
Category Example
System measures c Image quality
c Dynamic range
c Modulation transfer function
Component measures
(not inclusive)
c Cinefilm sensitometry
c Cinefilm spatial resolution
c Fluoro spatial resolution
c Fluoro field of view size accuracy
c Low-contrast video resolution
c Cine and fluoro automatic exposure control
Table 9. Essential Data Elements for a Quality
Improvement Program
c Individual operator procedural volume and major complication rate
c Institutional procedural complication rate
c Relevant clinical and demographic information
c Verification of data accuracy
c Patient and operator confidentiality
c Comparison of outcomes with benchmark data
c Ability to risk-stratify patients
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tional adult cardiology have been developed, is properly
focused on proficiency, both cognitive and technical. For
coronary interventional procedures, proficiency is intimately
related to procedural volume, although the latter is not
synonymous with the former. However, sound quantitative
support now exists for these once presumed arbitrary cut
points. The situation is less clear with respect to diagnostic
catheterization. Given the absence of similar quantitative
data for diagnostic procedures, as well as the significantly
lower associated morbidity and mortality associated with
diagnostic catheterization, operator proficiency may be bet-
ter assessed in a larger overall context. Rates of normal
studies, peer review of diagnostic quality of studies, rates of
referral for intervention, and perhaps development of crite-
ria of the appropriateness of these studies are suggested as
methods of incorporating physician practice into the QI
process of diagnostic procedures. It is recognized that the
latter depends critically on the development of locale-
specific “pathways” of care. However, “outliers” in this
process may be readily identified and constructively advised.
Standards of performance and QA in either a diagnostic or
an interventional catheterization laboratory must of course
originate with the individual. However, processes for cre-
dentialing activity and the ongoing assessment of profi-
ciency must be developed in accord with both local gover-
nance policies, as well as professionally developed standards.
In particular, the granting of privileges by healthcare sys-
tems is properly within the legal and ethical purview of these
institutions. It is hoped that these systems use criteria similar to
those outlined in this document to support the decision to
credential physicians and monitor system performance.
The key elements of such a program are: 1) the develop-
ment of a consensus on variables that reflects quality of care,
2) the rigorous prospective collection of these variables, 3)
appropriate statistical analysis of the data to identify defi-
ciencies in the process of care, 4) the development of a
multidisciplinary approach to problem solving, 5) subse-
quent data collection with analysis of the specific effect of
the solution on the identified deficiency, and 6) benchmark-
ing of the information against national database standards
such as the ACC National Cardiovascular Data Registry
(44). These data are perhaps best presented to involved
practitioners at regularly scheduled conferences for appro-
priate critique and problem solving.
Over a 10-year period, improvements in instrumentation,
imaging, data recording, and procedural outcomes have
proceeded rapidly. Consequently, continuing education for
practitioners beyond the level of training programs has
become the norm for the acquisition of many of these skills.
Training programs themselves are changing from the tradi-
tional 1-year program in interventional cardiology to 2-year
programs in some institutions. The development of sub-
subspecialty certification boards in interventional cardiology
reflects this burgeoning knowledge base. All of this trans-
lates into the need to provide continuing education to all
members of the team. The implementation of new technol-
ogy requires a critical evaluation of both the experience in
the literature as well as experience within individual insti-
tutions. An organized program of didactics coupled with
cautious early clinical experience is an ideal mechanism for
the introduction of new therapies. These types of programs
in conjunction with attendance at regional or national
scientific meetings devoted to the unbiased presentation of
new data provide a solid infrastructure for credentialing
purposes. Attention to this aspect of laboratory QI is critical
to maintaining both expertise and morale.
A recent review of cardiac catheterization laboratory
settings has outlined certain practical lessons learned by the
Laboratory Survey Committee of the SCA&I (45). This
committee noted that the major QA problems were usually
not related to equipment but rather to inadequate laboratory
space, lack of a physician medical director, lack of specific
operating rules for the laboratory space, and lack of a
functioning QA program. Not only must a QA program
provide procedural complication information, but a feed-
back mechanism to modify behavior must be in place.
Benchmark data are important, and because these bench-
mark data are dependent on a high number of participating
laboratories, the Committee strongly recommends that
cardiac catheterization laboratories actively participate in
the national data registries, such as the ACC NCDR.
D. Minimum Caseload Volumes
The use of a specific minimum number of cases to define
the quality of operator performance is obviously fraught
with problems. Because many laboratories may not adhere
to appropriate oversight or may not have an established QA
program, it has become popular to define minimum case-
loads for both the operators and the laboratory in place of
many of the issues described in detail earlier. Given the low
risk for diagnostic cardiac catheterization, the Committee
could not arrive at any consensus as to what would consti-
tute a minimum workload for individuals with regard to
diagnostic procedures. There have been no data to justify
the prior recommendation of at least 150 cases/year (5). The
minimum diagnostic caseload for the entire laboratory also
varies widely from state to state, often depending on the
presence of the certificate of need (CON) process or other
occasionally arbitrary requirements. It falls upon the director
of the laboratory to ensure that all studies in the cardiac
catheterization laboratory are of the highest quality. In
general, high-volume laboratories have consistently been
shown to have fewer complications than low-volume facil-
ities, although quality cannot be deciphered by observing
the total laboratory volume alone (2).
Recommendations regarding interventional volumes are
noted in Table 7. In general, the Committee thought that
the minimum interventional caseload of 75 procedures/year
for operators and a minimum performance of 200 cases/year
by institutions, with the ideal being 400 cases/year per
laboratory, both reasonable and supportable, based on cur-
rent data (3,46). This minimum caseload for operators has
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also been adopted by the ABIM as a prerequisite for
eligibility to take the interventional boards.
Issues of training, competency, and operator volume are
important. It was estimated that 6,100 physicians performed
428,000 interventional procedures in 1994. These physi-
cians represented 40% of board-certified cardiologists in the
U.S. (28). Over half of the physicians performing interven-
tional procedures in the U.S. at that time did not meet the
current minimum suggested volume recommendations for
proficiency within the catheterization laboratory. Operators
performing a low volume of interventions might be tempted
to expand the indications for diagnostic or interventional
procedures in their clinical practice, yet a more aggressive
approach to invasive therapies may or may not be in the
patient’s best interest. Under these circumstances, low-volume
operators may wish to consolidate practices and dedicate 1
individual to perform catheterization-related procedures in-
stead of having multiple physicians perform such procedures.
The ACC/AHA guidelines for PCI (3) have reviewed
this issue in depth, noting multiple studies that support a
relationship between complications and procedural volume.
The lowest complication rates are observed when interven-
tional procedures are performed by higher-volume operators
($75 cases/year) with advanced skills (e.g., subspecialty
certification) at high-volume institutions. This concept has
also been endorsed by the ACC/AHA Task Force on
Practice Guidelines for Coronary Angiography and the
SCA&I (18,45). Ideally, lower-volume operators (,75
cases/year) should only work at institutions that perform
.600 procedures/year (3). Even in the high-volume setting,
low-volume operators should develop a defining mentoring
relationship with a highly experienced operator who per-
forms .150 procedures/year (3).
V. PROCEDURAL ISSUES IN THE PERFORMANCE OF
CARDIAC CATHETERIZATION
Although no rigid protocol is commonly followed for all
patients or environments, some general procedural issues are
pertinent to most cardiac catheterizations. The following
discussion is meant to provide a general approach to some of
the issues that frequently arise in the performance of cardiac
catheterization.
A. Patient Preparation
1. Sedatives and Relaxants. Appropriate sedation ensures
the comfort of the patient during the procedure. Initial
premedication with diphenhydramine (Benadrylt) and/or
diazepam (Valiumt) is used in most catheterizations be-
cause of their respective antiallergic and sedative properties.
If more sedation or relaxation is necessary once the patient
is in the catheterization laboratory setting, additional seda-
tives can be given. Conscious-sedation protocols should be
followed, with documentation of vital signs and oxygen
saturations during the study in accordance with individual
institutional guidelines. Alternative sedatives often used
during the procedure include IV midazolam (Versedt),
hydromorphone hydrochloride (Dilaudidt), and fentanyl
citrate. Excessive sedation should be avoided so that the
patient’s state of consciousness is not severely altered, which
would render the patient unable to report discomfort or
symptoms that might herald a potential complication during
the procedure. All patients should have pulse oximetry
monitoring during conscious sedation, with periodic checks
of blood pressure, heart rate, and blood oxygen saturation
documented during the procedure (47).
2. Prevention of Contrast “Allergy”. The preprocedural
history should document any previous exposure to X-ray
contrast and whether any reaction occurred. A complete
description of the allergic reaction should be obtained to
ascertain its validity and importance. When patients have
previously had an allergic reaction to intravenously admin-
istered contrast material, a subsequent allergic reaction to
intra-arterially administered radiographic contrast is rare,
but these patients are at higher risk (48).
Given the rarity of true contrast-allergic reactions in the
cardiac catheterization laboratory, it is difficult to recom-
mend a preventive therapy with confidence. There are data
that suggest that premedication with steroids before the
administration of radiographic contrast for IV pyelography
reduces contrast reactions in high-risk patients (49). This
has led to the recommendation to administer an oral steroid
1 to 2 days before the procedure to patients at risk. In most
cardiac catheterization laboratories, however, steroids are
often only given intravenously a few h (or less) before the
procedure. There are no data to support or refute the
advantages of this practice. In addition, diphenhydramine
(Benadrylt) and cimetidine (Tagamett) or much more
potent H1 and H2 blockers are often used to further reduce
the possibility of an allergic reaction (50).
In addition to these precautions, a few laboratories give a
1-mL test dose of the contrast agent intra-arterially, then
follow it with a 3-min observation period to watch for any
signs of an anaphylactoid reaction (49). Anaphylactoid
reactions are characterized by profound hypotension, hives,
and bronchospasm. Treatment includes administration of
large volumes of fluid to restore blood pressure. Antihista-
mines and epinephrine are also used to reduce the urticarial
reaction and resulting bronchospasm. Anaphylactoid reac-
tions must be differentiated from vagal reactions, a common
event during the initial stages of the catheterization proce-
dure, or contrast-induced bradycardia and hypotension,
especially during coronary injections that involve the atrio-
ventricular nodal artery. Anaphylactoid reactions generally
result in more profound hypotension and are more pro-
longed than vagal episodes. Anaphylactoid reactions may
not respond to the use of atropine and fluids, as would be
expected with a vagal reaction. Tachycardia is usually
present during anaphylactoid reactions, as opposed to the
bradycardia seen with stimulation of the vagus nerve.
3. Patients With Renal Insufficiency. Patients with
known renal insufficiency (creatinine .1.8 mg/dL) should
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be treated with preprocedural and postprocedural hydration
and observed. There is suggestive evidence that there may
be an advantage in the use of nonionic contrast compared
with ionic contrast agents in these patients (50–52). Dia-
betic patients with renal dysfunction are at particularly high
risk for acute renal failure after exposure to contrast agents
(53). The amount of contrast used during the study should
be minimized, and if possible, a biplane laboratory should be
used to obtain the maximum information with each injec-
tion. Eliminating left ventriculography may further mini-
mize the contrast load because the same information may be
available from noninvasive studies. Postprocedural hydra-
tion should be considered in all cases and is mandatory in
patients with severe renal dysfunction. Because the rise in
creatinine level after the use of radiographic contrast may
continue for up to 72 or more h after the procedure,
appropriate laboratory follow-up to document any late
worsening of renal function should be arranged for those at
risk. Pretreatment with acetylcysteine holds promise for
reducing the risk of contrast nephrotoxicity (54), although
confirmatory data are needed to validate this approach.
Despite the popularity of ad hoc interventional procedures
after a diagnostic angiogram, this practice should be dis-
couraged in patients with renal insufficiency (in a nonemer-
gent setting) to prevent excessive use of contrast.
4. Patients With Diabetes Mellitus. In patients who are
insulin dependent, the dosage of insulin should be adjusted
to correspond with food intake before the procedure, and if
possible, catheterization for these patients should be sched-
uled early in the day to avoid a long period of altered food
intake and insulin administration. Often half of the usual
insulin dosage is administered on the morning of the
procedure. Blood sugar should be monitored if any symp-
toms of hypoglycemia emerge. In patients with diabetes
who take metformin (Glucophaget), there is a potential for
development of profound lactic acidosis should contrast-
induced renal dysfunction develop. As a position paper from
the SCA&I points out, this is an extremely rare event and
has occurred only in patients with abnormal renal function
(55). Metformin is relatively contraindicated in diabetic
patients with significant renal insufficiency. Because of the
potential hazard, however, the current recommendation is
that metformin be discontinued the morning of the proce-
dure and not restarted until the creatinine level is shown to
be stable, usually 48 h after the procedure (55).
5. Patients Receiving Antiplatelet or Antithrombotic
Medications. Patients who take warfarin (Coumadint)
should generally discontinue their drug for 3 doses before
the cardiac catheterization procedure. An acceptable INR
just before the cardiac catheterization varies according to
individual practitioners, but the consensus is that an INR of
,1.8 is acceptable without an increased risk of bleeding
after the procedure. The overuse of vitamin K reversal of
warfarin effects may make it difficult to re-establish a
warfarin effect afterward. Patients receiving heparin may
undergo cardiac catheterization without concern, although
longer periods are required for hemostasis, and reversal of
the heparin effects with protamine sulfate after completion
of the study may be warranted. Closure devices may also
help reduce groin bleeding in certain situations (56). Hep-
arin activity may be estimated by the ACT. A fully
heparinized patient in the cardiac catheterization laboratory
would be expected to have an ACT .300 s, while it is
generally safe to remove the catheters and sheaths once the
ACT is ,175 s. Heparin can be reversed by protamine, but
profound allergic reactions may occur, especially in diabetic
patients receiving NPH insulin (57). Aspirin is not stopped
before cardiac catheterization. Use of the newer antiplatelet
agents such as ticlopidine (Ticlidt), clopidogrel (Plavixt),
eptifibatide (Integrilint), tirofiban (Aggrastatt), or abcix-
imab (ReoProt), does not preclude a patient from under-
going cardiac catheterization; although the combination of
GP IIb/IIIa inhibitors and standard heparin dosage (100
U/kg) results in a higher rate of groin bleeding complica-
tions (29). In patients receiving GP IIa/IIIb inhibitors, the
heparin dose should be reduced to 70 U/kg.
B. Procedural Issues
1. Sterile Preparation of the Access Site and Vascular
Access. Infection is rare after invasive cardiovascular pro-
cedures. In a retrospective study of 385 laboratories, an
infection rate of 0.35% was noted, with the incidence for
cut-downs 10 times higher than that for percutaneous sites
(0.62% vs. 0.06%) (58). The Occupational Safety and
Health Administration (OSHA) recommends that prepa-
ration of all patients include the removal of hair from the
site, application of antiseptic to the skin, and the use of
sterile drapes. Systemic antibiotics are not required, al-
though some operators use them with large-vessel noncoro-
nary stents or other devices that will be left in the body.
Operators should wear a sterile scrub suit. A generally sterile
environment should be maintained during the procedure.
Disposal of all materials should also follow local safety and
infection control guidelines.
Although the sterile techniques used in the operating
room are not necessary for most cardiac catheterization
laboratory procedures, the operator should use appropriate
hand washing and wear a sterile gown and gloves. Masks,
eye shields, and protective caps are probably more important
for keeping the patient’s blood from splattering onto the
operator than for protecting the patient from infection. In
cases where greater wound exposure is necessary, such as
pacemaker implantation or brachial cut-downs, the full
surgical sterile technique should be used. A vascular sheath
should be used to minimize vascular trauma, especially when
multiple catheter changes are anticipated. Each percutane-
ous vascular site (femoral, brachial, radial, subclavian, trans-
hepatic, or internal jugular) requires that the operator have
specialized training. Although some aspects of percutaneous
vascular access are similar for all sites, certain issues (e.g.,
compression and/or administration of heparin or intravas-
cular verapamil or nitroglycerin) are unique to each site.
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The Sones brachial cut-down technique has largely been
replaced by percutaneous methods. The Sones cut-down
technique requires more specialized training, proctorship,
and credentialing because of the unique training and skill
level necessary for its safe use. This technique requires a
more extended skin incision, blunt dissection, and arteriot-
omy and repair. Currently, the most common site for
percutaneous arterial access for both diagnostic and inter-
ventional cardiac procedures is the femoral artery region.
The radial artery approach is gaining some favor, especially
for obese patients and outpatients. If venous access is
required, in most cases it should be performed using the
femoral vein or the internal jugular vein. Multiple venous
catheters can be safely inserted in the same femoral vein;
multiple arterial catheters require separate arterial access sites.
Strict sterile procedures should be followed at each site.
2. Right-Heart Catheterization During the Evaluation of
Coronary Artery Disease. The routine use of right-heart
catheterization in a patient whose symptoms and objective
studies suggest coronary artery disease without associated
mitral regurgitation or congestive heart failure is discour-
aged (59). The additional information gained from a right-
heart catheterization in patients with chest pain and sus-
pected coronary artery disease is minimal. Unless
concomitant valvular heart disease, presumed pulmonary
hypertension, intracardiac shunts, or other diagnoses are
suspected, a routine right-heart catheterization should not
be performed. If it is anticipated that knowledge of right-
heart pressures and cardiac output would be helpful in
patients with left ventricular dysfunction and provide infor-
mation that would enhance the safety of the procedure or
affect decision making afterward, right-heart catheterization
is acceptable.
3. The Routine Use of Temporary Pacing. Routine use of
a temporary pacemaker during coronary angiography or
interventional procedures is not indicated. However, use of
a rotational atherectomy device (60) in right coronary artery
disease or use of the Angiojet device (61) has been associ-
ated with an increased incidence of atrioventricular block.
This is also true during percutaneous aortic balloon valvu-
loplasty or with alcohol ablation for hypertrophic cardiomy-
opathy. Thus, temporary pacing may be warranted in these
instances. In patients with left bundle-branch block in
whom a right-heart catheterization is being performed,
there is a clear risk of complete heart block if the right
bundle branch is injured during the procedure. Thus,
temporary placement of a pacemaker may be appropriate. If
it is anticipated that catheter manipulation or coronary
obstruction during an interventional procedure might pro-
duce a bradyarrhythmia for which a temporary transvenous
pacemaker would be necessary, a temporary pacemaker
should be positioned before the need arises.
4. Transseptal Cardiac Catheterization and Percutane-
ous Balloon Mitral Valvuloplasty. The need for transsep-
tal cardiac catheterization has persisted with the necessity of
percutaneous mitral balloon valvuloplasty and the need to
enter the left atrium during certain electrophysiological
procedures. The technique is also useful in congenital heart
disease and when left ventricular pressures and angiography
are vital in patients with disk-type prosthetic aortic valve
replacements. The technique is safe when performed by
experienced operators (21).
Although percutaneous balloon mitral valvuloplasty can
also be performed transseptally via the internal jugular vein
(62) or retrogradely across the mitral valve via the arterial
system (63), most procedures use the transseptal technique
from the femoral vein. Single-balloon (primarily Inoue) or
double-balloon methods are both effective (64). The Com-
mittee is not aware of any specific data regarding the
minimum numbers for competency because the procedure
is, for the most part, limited to major medical centers with
a specific interest and expertise. Previous guidelines (5)
suggested a minimum caseload of 25/year, and although this
seems reasonable, there are no data to support this number.
As with many “orphan” procedures, it is critical that the QA
system be operative and that all transseptal procedures be
closely monitored and any complications reviewed. Percu-
taneous balloon mitral valvuloplasty carries a small but
well-documented risk (65), and its performance should be
restricted to those operators who are aware of the appropri-
ate indications for the procedure, skilled in the technique,
and capable of handling any complications that may arise.
5. Role of Left Ventricular Puncture in the Era of
Echocardiography. In the current era, the information
gained from both transthoracic and transesophageal echo-
cardiography allows for an excellent estimation of ventric-
ular function and a reasonable sense of the severity of
stenotic or regurgitant valvular lesions. The use of direct left
ventricular puncture thus provides minimal additional in-
formation beyond that gained by echocardiography yet
exponentially increases the chance of a serious complication
even in experienced hands. The need most often arises in
patients with 2 disk-type prosthetic mitral and aortic valves
that prevent left ventricular access by any other means. It is
the consensus of the Committee that left ventricular punc-
ture should be used only in very rare instances in which the
information needed to make a diagnostic or therapeutic
decision is not available by any noninvasive method.
6. Use of Provocative Agents During Diagnostic Cardiac
Catheterization. Certain provocative pharmacological
agents may be used during cardiac catheterization to un-
mask pathology that is not evident without the intervention.
Fluid loading may unmask latent pericardial constriction or
tamponade. Afterload reduction or inotropic stimulation
may be used to increase the outflow tract gradient in
hypertrophic cardiomyopathy. Similarly, the use of afterload
reduction or an inotropic agent may assist in the assessment
of the severity of aortic stenosis in patients with low cardiac
output and low transvalvular gradient (66). The use of
provocative coronary vasoreactive agents (e.g., methyler-
gonovine, acetylcholine, adenosine, or papaverine) should
be confined to situations in which specific coronary artery
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questions are being asked, because they have little clinical
utility otherwise. Measures of coronary flow reserve or
pressure-derived fractional flow reserve (FFR), by use of
methods such as the Doppler or pressure sensor guidewires
often require the use of coronary vasodilators such as
adenosine, dipyridamole, or papaverine. A variety of pul-
monary vasoreactive agents (e.g., oxygen, calcium channel
blockers, adenosine, nitric oxide, or prostacyclin) may help
define prognosis and potential responders to drug therapy in
patients with primary pulmonary hypertension (67). These
agents are only now being studied in secondary pulmonary
vascular disease. The use of any of these agents carries
potential risks, and the risk/benefit ratio of the procedure
must be determined by the individual cardiologist. In each
case, however, the catheterization laboratory committee
should have a detailed and approved procedural protocol for
the use of these agents. This protocol should include the
steps to be taken immediately to treat any potential com-
plications that may arise.
7. Operator Safety During Cardiac Catheterization in
Patients With Communicable Diseases. All cardiac cath-
eterization procedures must be conducted as if there were a
risk of infection. Heightened protective care should be taken
in any case in which a communicable disease such as
hepatitis or human immunodeficiency virus (HIV) positivity
is present. Because there is no assurance that individual
patients without these diagnoses do not carry a serious
communicable disease such as HIV, the prudent operator
must always use optimum care during each study. Every
cardiac catheterization laboratory should have an approved
additional sterile technique protocol for known highly
infectious cases. This protocol should include the use of
surgical caps and masks, as well as eye protection. Double
gloving has been shown to reduce the chances of a puncture.
In addition to the usual surgical gown, disposable shoe
covers for the cardiologist and all technicians in the room
should be considered. The careful disposal of all needles,
catheters, sheaths, tubing, and other instruments, as well as
fluids that come in contact with the infected patient is
obviously important. Extra clean-up of the laboratory space
should also be performed before it is used again.
C. Performance Issues
1. Injection of Coronary Arteries. The safe injection of a
contrast agent into coronary arteries is predicated on the
coaxial placement of the coronary catheter in the coronary
ostium and the correct positioning of the tip of the catheter
in the coronary artery. Assurance of a bubble-free connec-
tion between the contrast manifold port or syringe and the
catheter must be established. Careful replenishment of
contrast in the injection syringe and the maintenance of a
bubble-free environment is the responsibility of the operat-
ing cardiologist. Most invasive cardiologists inject the cor-
onary arteries manually, although power injectors can be
used safely with appropriate equipment and training. Cor-
onary injections should include a tiny test dose of contrast
once the catheter tip is in position to be certain that the
catheter is not subintimal or under a plaque that might
result in an extensive coronary artery dissection if a full
injection of contrast were administered. Monitoring cathe-
ter tip pressure is obligatory. A “flush” injection into the
respective coronary sinus may help define ostial coronary
disease.
The use of nurses, cardiovascular technicians, or physi-
cian’s assistants to inject the coronary arteries has become
increasingly popular. It remains the responsibility of the
individual invasive cardiologist to ascertain whether para-
medical personnel or power injectors are capable of admin-
istering contrast into the coronary arteries. Physician ex-
tenders should always be viewed as extensions of the
primary operator’s hands, with the responsibility for safety
ultimately residing with the invasive cardiologist.
2. Angiography. In the majority of cases, the use of
single-plane X-ray imaging is satisfactory, recognizing that
many laboratories do not have biplane capabilities. Labora-
tories contemplating angiographic evaluation of patients
with congenital heart disease, however, should have biplane
capabilities. In the case of left ventriculography in patients
with coronary artery disease, an appropriate view should be
selected to gain the most information regarding left ven-
tricular function.
The use of multiple orthogonal views of the coronary
arteries is of obvious importance. The invasive cardiologist
must be certain that appropriate information is obtained and
recorded in order to make an accurate diagnosis and help
determine suitability for PCI. Each segment of the coronary
artery should be seen in at least 2 orthogonal views.
Angulation to obtain the “worst stenosis” of any lesion is
important. Although it may be helpful and expeditious to
have routine views performed on each coronary study,
additional views should be obtained if the anatomy is not
clearly presented or there are overlapping structures. The
knowledge and application of additional views is the hall-
mark of excellence for angiographers (68). Table 10 lists
suggested appropriate views of each coronary as a guideline.
In the case of right-heart and pulmonary angiography, it
is important that the appropriate views be obtained to
demonstrate the anatomy being interrogated. Because most
cardiac catheterization laboratories have only a 9-inch image
intensifier, multiple images of the lung are usually required
to interrogate the entire lung fields. If the aorta is to be
investigated, cine aortography can be performed in the
catheterization laboratory to ascertain the size of the aorta
(in cases of aortic stenosis with anticipated aortic valve
replacement) and to visualize the arch vessels. If detailed
examination of the lung and aorta and arch vessels is
required, it is often better to use a system with a larger-size
image intensifier designed for that purpose.
Because there is considerable degradation in the image
quality when copies of cineangiograms are transferred onto
videotape, diagnostic decisions are best made on original
cinefilm or digital media.
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3. Pressure Measurement. The importance of high-
quality pressure measurements unfortunately has been de-
emphasized in many laboratory facilities. The availability of
numerous types of hemodynamic equipment precludes de-
tailed description here. Appropriate filtering of the hemo-
dynamic signal is important for adequate interpretation of
individual waveforms. Careful balancing and zeroing of the
system at the level of the atria are necessary for each
procedure. Often simultaneous pressures are important, and
frequently higher-speed recordings (100 mm/s) are needed
to obtain adequate data for waveform analysis. It is the
responsibility of the laboratory director to ensure that the
equipment available produces the information desired. De-
tailed knowledge of each laboratory’s transducers and re-
corders should be part of the requirement for credentialing
of invasive cardiologists in a particular catheterization lab-
oratory. It is each invasive cardiologist’s responsibility to
direct the acquisition of appropriate pressures. Invasive
cardiologists using the laboratory should review the quality
of the pressure recordings obtained, and any deficiency
should be corrected by the company providing the equip-
ment.
During a routine left-heart and coronary arterial cathe-
terization, a preprocedural and postprocedural aortic pres-
sure tracing as well as the recording of the left ventricular
systolic and end-diastolic pressure should be obtained.
Some laboratories find it useful to repeat the left ventricular
pressure after the left ventriculogram, although the actual
value of this exercise is questionable. During right-heart
catheterization, the acquisition of right atrial, right ventric-
ular, pulmonary artery, and pulmonary artery wedge tracings
is routine, and sufficiently long strips of phasic recordings
should be obtained to assess respiratory variation. Obtaining
the end-expiratory pressure may help reduce the respiratory
variation, although some patients are unable to hold their
breath without performing a Valsalva maneuver, and thus
the pressures are influenced by the resultant high intratho-
racic pressure generated. The mean pressure in atrial and
pulmonary chambers should be obtained over 10 beats to
allow for correction of respiratory changes. If pullback
pressures are used to measure valvular gradients, the patient
should be in as steady a state as possible to diminish the
likelihood of any respiratory variation between pressure
measurements from one chamber to another. Simultaneous
pressures to gauge gradients across valvular lesions are
preferred. Care should be taken if the femoral artery
pressure is used as a substitute for aortic pressure in younger
patients. If femoral pressure is to be used as the aortic
pressure surrogate, documentation should be obtained that
the pressures between the 2 sites are similar. On occasion,
the pulmonary capillary wedge pressure will also not corre-
spond well to the left atrial pressure (especially after mitral
valve replacement), and a transseptal puncture with simul-
taneous measurement of the left atrial and left ventricular
pressure is required for an accurate transmitral gradient.
Rarely a pressure gradient across a lesion in a coronary
vessel may provide information regarding the hemodynamic
significance of that lesion. Coronary pressure wires and flow
wires may be used to help evaluate severity of coronary
stenosis.
4. Measurement of Cardiac Output. Cardiac output mea-
surements commonly used in the cardiac catheterization
Table 10. Suggested Views for Coronary Angiography
Coronary Artery Suggested Views
Left Main
c Ostial Shallow RAO; LAO cranial; AP caudal
c Body RAO shallow/caudal/cranial; AP
c Distal LAO caudal/cranial; RAO caudal
Left Anterior Descending
c Ostial/proximal diagonals Cranial LAO; RAO shallow/cranial/lateral
c Proximal/mid diagonals LAO cranial; RAO cranial/lateral
c Distal/apical RAO lateral
Left Circumflex
c Ostial/proximal LAO; LAO cranial/caudal
c Ostial/ramus LAO; LAO caudal; RAO caudal
c Mid/marginals RAO shallow/caudal; LAO caudal
c Distal (dominant) LAO shallow/cranial; RAO shallow/caudal
Right Coronary
c Ostial/proximal LAO; LAO cranial; left lateral
c Mid LAO; LAO cranial; RAO shallow; left lateral
c Distal/bifurcation of posterior descending LAO cranial; RAO shallow/lateral; AP caudal
c Posterior descending RAO shallow; LAO cranial; AP caudal
c Posterolateral to left ventricle RAO shallow; LAO cranial; AP caudal
Angulation refers to the location of the image intensifier relative to the patient: AP 5 antero-posterior; Caudal 5 toward the
feet; Cranial 5 toward the head; LAO 5 left anterior oblique; Lateral 5 90° from vertical; RAO 5 right anterior oblique;
Shallow 5 15° to 30° angulation from vertical with neither caudal or cranial angulation.
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laboratory include the use of indicator dilution methods
(typically thermodilution), the Fick method (use of pulmo-
nary and arterial blood oxygen saturations and oxygen
consumption), angiographic methods, and impedance esti-
mates. Indocyanine green dye is now rarely used. As a
consequence, most cardiac catheterization laboratories rely
on thermodilution methods or the Fick method for deter-
mination of cardiac outputs. Thermodilution methods use a
thermistor on the end of a right-heart catheter. As a
proximally injected bolus of saline traverses past the ther-
mistor, the temperature change results in a curve similar to
that observed with dye dilution methodology. Analysis of
this curve allows determination of cardiac output by a
variety of methods. Accurate measurement requires a con-
centrated bolus of saline. Thus, tricuspid or pulmonary
insufficiency may significantly alter the results obtained.
Fick cardiac outputs require measurement of oxygen satu-
ration, hemoglobin, and oxygen consumption. Oxygen con-
sumption is usually the most difficult variable to obtain.
Most laboratories use an assumed value, either from an
established reference table or the following formula: oxygen
consumption 5 125 mL/min/m2 BSA. Direct measurement
of oxygen consumption provides a more accurate assessment
using a variety of instruments, but the unstable nature of
some of these devices and the expense and time involved
have discouraged direct oxygen consumption measurements
in most catheterization laboratories. Angiographic cardiac
output using area-length assumptions or Simpson’s rule
provides left ventricular volumetric data useful for estimat-
ing valvular stenosis severity in the presence of valvular
regurgitation (assuming only 1 left-sided valve demonstrates
regurgitation). The regurgitant fraction can also be derived.
Angiographic methods suffer from vagaries in the accuracy
of the prolated ellipse shape assumptions and from the
determination of the requisite correction factors needed
because of X-ray divergence. Whatever method is used for
determining cardiac output should be well understood by all
personnel. Each cardiac output method has limitations and
errors that can be minimized with careful attention to the
inherent vagaries of each technique.
D. Postprocedural Issues
1. Vascular Hemostasis. The most frequent complication
of coronary angiography and coronary interventions occurs
at the vascular access site. Careful vascular entry is the first
guard against such complications. Unfortunately, the use of
heparin and/or thrombolytic or antiplatelet agents sets the
stage for vascular complications (see Tables 5 and 6).
Vascular hemostasis obtained after the procedure should be
viewed as a crucial component of the procedure. In cases of
femoral puncture, where a vascular closure device is not
used, it should be routine to assess the influence of proce-
dural heparin using the ACT value before access-site
compression. Once the ACT has returned to near normal
(,175 s), sheaths can be removed and manual pressure or
mechanical pressure clamps applied. If lytic agents have been
used, prolonged vascular compression may be necessary. Most
patients should be confined to bed for a minimum of 2 h after
the procedure. The use of the radial or brachial artery ap-
proaches obviates the need for prolonged bed rest, but hemo-
stasis must still be achieved by manual or device pressure.
The use of percutaneous vascular closure devices is
becoming increasingly popular, and although these devices
carry their own set of complications, they provide excellent
hemostasis and allow for early ambulation of most patients.
Operators who use vascular closure devices should first
undergo careful training and proctorship before accredita-
tion. Table 11 outlines some general recommendations
regarding postprocedural hemostasis after femoral artery
access.
In cases of both diagnostic and interventional procedures,
it is the responsibility of the QA program to ascertain that
careful clinical follow-up during time in-hospital and for 24 h
after the procedure are reported in terms of vascular compli-
cations for each practitioner and the laboratory as a whole.
2. Reporting of Cardiac Catheterization Results. The
formal cardiac catheterization and angiographic report
should contain a certain critical amount of information. The
indication for the procedure should be clearly stated. The
time course of the procedural events should be documented
and recorded. The time and dose of all medications used
Table 11. General Recommendations Regarding Postprocedural Hemostasis After Prior Femoral
Artery Access
Situation Recommendation
Following hemostatic closure device 1–2 h recumbent in position of comfort, then
ambulate 3 30 min before discharge
Following removal of venous sheath 1 h with leg straight, then ambulate 3 30 min before
discharge
Following removal of femoral arterial sheath
(ACT ,175 s)
Manual compression 10–20 min (until hemostasis achieved)
Clamp 15 min to 1 h to achieve hemostasis
Bedrest Leg straight, slight head elevation 3 2–6 h
Ambulation 30 min to 1 h before discharge
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during the procedure should be noted. All catheters,
sheaths, and special guidewires used should be reported in a
procedural section. Any pertinent hemodynamic data ob-
tained should also be reported. The minimum hemody-
namic data that should be reported from a left-heart
catheterization and coronary angiography study with left
ventriculography should be the initial and ending aortic
pressures and the left ventricular systolic and end-diastolic
pressure. If right-heart catheterization is performed, the
right atrial, pulmonary artery, and pulmonary artery wedge
pressure values should be reported, as well as mean pres-
sures. The right ventricular pressure should include the
systolic and end-diastolic pressures. Transvalvular mean and
peak pressure gradients and valve area determinations
should be reported when appropriate, along with the cardiac
output determination and any shunt data if indicated.
In addition to a detailed summary of the procedure, a
description of the angiographic findings is required. A visual
diagram of the coronary tree is helpful to communicate
vascular anatomy and lesion location. Minimum findings to
be reported should include: 1) the presence or absence of the
right and left coronary ostia and detailed descriptions of any
abnormalities in the left main coronary artery; 2) the left
anterior descending coronary artery and its diagonal and
septal branches; 3) the left circumflex coronary artery and its
obtuse marginals and inferolateral branches; and 4) the right
coronary artery and its posterior descending and posterolat-
eral branches. The dominance of the coronary vessels should
also be noted. The left ventriculogram assessment should
include the regional wall motion abnormalities seen in the
left ventricle contour in terms of anterior, inferior, apical,
posterior, and lateral segments. Terminology for each seg-
ment should include normal, hypokinesia, akinesia, dyski-
nesia, and aneurysmal wall motion. Quantitative methods
are also useful when available. A measured or estimated
ejection fraction should also be reported and the presence
and severity of any valvular regurgitation noted. Pertinent
additional details such as calcium in the coronary arteries,
valves, or pericardium should also be included if these data
have potential clinical relevance. A final diagnosis should be
clearly stated. In some laboratories, the management deci-
sion is also included in the report.
Procedural and hemodynamic records should be stored in
some form for at least 7 years and should be accessible
within a reasonable time frame. Angiographic findings
should also be available for subsequent review for 7 years,
although the quality of cineangiograms clearly degrades over
time. The findings of catheterization or angiography should
be available to the patient and any physician or facility that
the patient so designates by written request.
VI. PERSONNEL ISSUES AND LABORATORY DESIGN
A certain critical mass of personnel is required to safely
perform cardiac catheterization. The following is an outline
of pertinent personnel requirements, roles, and obligations.
A. Attending Physician
The attending physician is the physician in charge of the
procedure. The attending physician is considered the pri-
mary operator for the procedure. He or she is a credentialed
physician, experienced in all aspects of the performance of
the procedure, including preprocedural and postprocedural
care of the patient.
B. Teaching Attending Physician
A teaching attending physician meets the requirements of
an attending physician in a program instructing graduate
physicians in the performance of the procedure and trans-
mission of information to the trainee physician(s). A teach-
ing attending physician must be present for all critical
aspects of the cardiac catheterization procedure.
C. Secondary Operators
Secondary operators are additional attending physicians
or physician extenders who assist the primary attending
physician. These physicians may fulfill the requirements for
an attending physician but are not in charge of the proce-
dure at hand and are not considered the primary operator.
They should not take credit for the case for the purpose of
fulfilling minimum performance volume requirements.
D. Laboratory Director
The laboratory director should be a physician with the
experience and leadership qualities needed to control the
laboratory environment (69). The director is charged with
the responsibility for policy development, quality control,
and fiscal administration. Depending on the type of labo-
ratory and type of patients studied, the director may be an
adult cardiologist or a pediatric cardiologist and may have
special interests such as in interventional cardiology or
electrophysiology. The director should be board certified
and thoroughly trained in cardiac radiographic imaging and
radiation protection. The director must be proficient in
performing procedures specific to the laboratory and must
be a skilled administrator supportive of the needs of the
departments served. The director’s qualifications should
include at least 5 years of catheterization experience and
recognized skill in the laboratory. Preferably, he or she
should be board certified in interventional cardiology if
interventional procedures are performed in the laboratory.
The duties and responsibilities of the director are multi-
ple and wide-ranging and demand strong management
skills. The director shall set criteria for granting privileges to
physicians and then review and make recommendations
about applications for those privileges. The director must
periodically review physicians’ performance, make recom-
mendations for renewal of laboratory privileges, review
performance of nonprofessional staff, and provide necessary
training to personnel. The director shall establish and
monitor quality control, including morbidity and mortality.
Other responsibilities include control of patient scheduling,
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procurement and maintenance of equipment and supplies,
budget preparation and monitoring, organization of regular
conferences for laboratory personnel, and regular reports on
laboratory activity. The director shall maintain communi-
cation and cooperation among laboratory staff, clinicians,
and the hospital administration to ensure that the patient is
best served. The director must designate a substitute who
will act in his or her absence.
E. Operating Physicians
As suggested in several recent documents (2,70–73), all
physicians credentialed to operate in the laboratory must
have proper training. This includes those classified as the
attending physician of record and those functioning as
teaching attending or secondary operators. This training
may be in adult or pediatric cardiology. Clinical training in
one of these fields should fulfill requirements for that
specialty board. The physician must also be trained in
emergency care and radiation physics and be certified as
competent by the program director of his or her training
institution. A laboratory physician should be a fully accred-
ited member of the hospital staff and ideally be specialty
certified or at least board eligible. A physician who would
provide only laboratory service without being a full member
of the hospital staff should not be granted laboratory
privileges. He or she must participate in the laboratory’s QA
program, including peer review. Physicians performing in-
terventional procedures should be board eligible or certified
in interventional cardiology.
F. Cardiovascular Trainee (Fellow)
The primary role of the cardiovascular trainee is to learn
cardiac catheterization procedures. The trainee also provides
preprocedural care, procedural performance, and postproce-
dural care. In so doing, trainees obtain the critical knowl-
edge and skills to become qualified attending physicians.
Trainees may perform all functions of the procedure as the
primary operator, but only under the direct supervision of a
credentialed physician who assumes responsibility for the
procedural results. The use of house staff not directly
engaged in a formal cardiovascular training program is
inappropriate. Table 12 outlines the current recommenda-
tions for training and maintaining proficiency in invasive
skills. All trainees should receive at least 4 months of
training and participate in 100 procedures (level I). For
diagnostic catheterization skills, trainees should perform
300 procedures, with 200 as the primary operator (level II).
For interventional catheterization skills at level III, trainees
are required to perform 250 interventional procedures as the
primary operator (74).
G. Use of Physician Extenders
(Physician’s Assistants and Nurse Practitioners)
Increasingly “physician extenders” (e.g., physician’s assis-
tants and nurse practitioners) are being used clinically as
secondary operators. It should be recognized that extenders
should never be primary operators. The physician extender
should be proficient in both the technical and cognitive
aspects of cardiac catheterization, including: 1) preproce-
dural evaluation, 2) indications, 3) cardiac physiology and
pathophysiology, 4) emergency cardiac care, 5) radiation
safety, and 6) application of diagnostic catheterization data
regarding the procedure, according to the standards estab-
lished by the SCA&I, ACC, and AHA (5,75,76).
Although there has been some controversy about whether
physician extenders are qualified to perform cardiac cathe-
terization and coronary angiography as primary operators in
lieu of physicians (75), it is the position of the Committee
that nonphysicians should not perform catheterization as
primary operators (76). The primary operating physician
must be in the catheterization suite during the procedure
when secondary operators are performing the procedure.
The primary physician operator must always be immediately
present to direct the physician extender and provide all
clinical decision making.
Specially trained nurses may assist attending physicians in
much the same role as physician’s assistants in the perfor-
Table 12. Levels of Operator Training and Proficiency in Adult Cardiac Catheterization and Coronary Intervention
Level Proficiency Level
Training
Yearly
Proficiency
Mos. of
Training
No. of
Diagnostic Cardiac
Catheterizations
No. of
Coronary
Interventions
No. of
Coronary
Interventions
Level I Basic training required of all trainees to be a competent,
consulting cardiologist
4 months 100 — —
Level II Additional training in diagnostic cardiac catheterization to
perform specific diagnostic procedures at an
intermediate level
12 months 300, with 200 as
primary operator
— —
Level III Advanced training in interventional cardiac catheterization
to perform, interpret and train others to perform and
interpret specific interventional coronary procedures at a
high skill level
12 months — 250 as primary
operator
$75 as primary
operator
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mance of procedures. They may be able to assist in place of
cardiovascular trainees, but they require greater supervi-
sion during all aspects of the procedure. Specialized
experience in both clinical care and cardiovascular pro-
cedures is required.
H. Nursing Personnel
The type and number of nursing personnel required in
the catheterization laboratory depend on the laboratory
caseload and mix and may include nurse practitioners,
registered nurses, licensed vocational or practical nurses, or
nursing assistants. In most laboratories, the nursing super-
visor is a registered nurse. This nurse must be familiar with
the overall function of the laboratory, help set the tone of
patient surroundings, and influence the efficiency and safety
of procedures. The registered nurse may also directly par-
ticipate in observation and nursing care of the patient during
catheterization and be ready to respond to any emergency.
The nursing supervisor should be in charge of the prepro-
cedure and postprocedure holding areas.
The background of a catheterization laboratory nurse
should include critical-care experience, knowledge of car-
diovascular medications, ability to start an IV infusion, and
experience in sterile techniques. Experience with vascular
catheter instrumentation, especially with identification,
cleaning, sterilization, and storage, is necessary. Knowledge
of vascular catheter materials and the proper size correla-
tions for catheters, guidewires, and adapters is important, as
is experience in the manipulation of manifolds, injection of
contrast, and changing of guidewires and catheters. The
catheterization laboratory nurse must have a thorough
understanding of the flushing of catheters and prevention of
clots or air emboli.
A licensed practical nurse with the proper background
and experience may have duties similar to those of the
registered nurse. However, a licensed practical nurse should
not supervise laboratory nursing. In some laboratories, an
appropriately trained nursing assistant may be responsible
for some duties. The nursing assistant may be a cardiopul-
monary technician who is familiar with procedures in
associated disciplines and is thereby able to function in the
dual capacity of cardiopulmonary technician and nursing
assistant.
I. Non-Nursing Personnel
Several kinds of technical knowledge are required in the
cardiac catheterization laboratory, although any one person
may not possess all the different types of technical expertise.
At least one technologist, who may or may not be a certified
radiological technologist, should be skilled in radiographic
and angiographic imaging principles and techniques. This
technologist should be experienced in the proper perfor-
mance of X-ray generators, cine pulse systems, image
intensification, automatic film-processing equipment (if
used), pressure injection systems, video systems, and cine
cameras. He or she, in cooperation with electronic and
radiological service engineers, should be responsible for
routine care and maintenance of the radiological equipment.
A basic ability to troubleshoot this equipment is advanta-
geous. This technologist, in cooperation with a radiation
physicist, should monitor radiation safety techniques for
both the patient and laboratory personnel. Immediate avail-
ability of a radiological engineer in the event of equipment
failure is highly desirable.
Laboratory technologists should be skilled in managing
blood samples, and performing blood gas measurements and
calculations. They should be qualified to monitor and record
electrocardiographic and hemodynamic data and have
enough skill and experience in interpreting these data to
report significant changes immediately to the physician
responsible for the patient. During any single procedure, the
monitoring technician or nurse must have no responsibility
other than monitoring and observing patient status. Train-
ing should include skills in patient observation and prepa-
ration for assistance in acute cardiac care, including resus-
citation and related therapeutic efforts.
In laboratories in which cinefilm is still used, at least 1
technologist should be skilled as a darkroom technician,
because the quality of images recorded on film is heavily
dependent on darkroom technique. This person must be
trained in photographic processing and the operation of
automatic film processors and must be familiar with the
characteristics of film and chemicals used for cardiovascular
procedures. Skills should be acquired in the techniques of
day-to-day calibration and maintenance of automatic pro-
cessors and the use of sensitometric/densitometric equip-
ment and data. These skills, plus skills in digital image
acquisition, storage, transfer, and processing are necessary
for the technologist to ensure high quality of the diagnostic
images. As laboratories move to a cineless environment, a
technician with computer skills is very valuable for handling
film transfer methods and archival storage devices and
equipment necessary to maintain the digital libraries and
produce compact discs or other transfer media when
needed. As all-digital laboratories become the norm over
the next few years, the role of the darkroom technician will
evolve into that of a digital archive technician. This will
undoubtedly require retraining and a new set of skills unlike
those needed in film development. Knowledge of X-ray
systems, acquisition of digital images, and handling of the
resultant digital information will remain important adjunct
skills.
J. Staffing Patterns
An invasive cardiologist must be present in the laboratory
during each procedure and must be responsible for the
outcome. To maintain effective and safe laboratory opera-
tion, each basic support function should be performed by
adequately trained personnel who constantly maintain their
skills and credentials. There should be adequate cross
training among laboratory staff so that personnel can rotate
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responsibilities and provide 24-h coverage of essential team
functions. Complex studies, especially those of children and
acutely unstable patients, require personnel with special
training to deal with the particular requirements of these
procedures. Frequently, the presence of a second physician
is important for optimal care in many such difficult cases.
K. Cardiopulmonary Resuscitation
All members of the catheterization team—physicians,
nurses, and technologists—should complete a course in
basic CPR. Certification in advance cardiac life support is
also strongly urged for all members of the cardiac catheter-
ization team. Yearly recertification is recommended.
L. Suggested Space Requirements
Table 13 outlines some suggested minimum room sizes
for the cardiac catheterization laboratory. It should be
obvious that these recommendations are only suggestions
and that space for development and access to newer tech-
nology will require modification. For instance, cinefilm and
record storage is gradually being replaced by computer
review stations and computer archival and retrieval areas.
Many physicians review digital angiographic results imme-
diately after the procedure in the control room, and this
capability means that control room space should be ex-
panded to accommodate this activity. Database require-
ments also require appropriate space for computers, not only
for data entry but also for compilation of the results and
preparation of the final catheterization report. Because most
diagnostic cardiac catheterization procedures have moved to
the outpatient environment, appropriate check-in, patient
waiting, and holding rooms have become necessary for any
cardiac catheterization suite. In some situations these areas
are shared with other areas of the hospital, such as ambu-
latory surgery or radiology; in others, these areas are
occupied solely by the cardiac catheterization laboratory.
Room heights are commensurate to room-need require-
ments. Procedure rooms require a minimum height of 9
feet, 10 inches. Heights of the control room and most other
rooms are generally 8 feet.
VII. ETHICAL CONCERNS
In medical school physicians are taught that their primary
obligations are to act in the best interest of the patient and
society (beneficence), to do no harm (nonmalfeasance), and
to maintain respect for patient autonomy (77–79). The last
obligation mandates that patients be given free and unco-
erced choices about their medical care and requires that
physicians provide accurate and unbiased information about
the patient’s medical condition, disclose alternative choices
and potential conflicts of interest, and obtain informed
consent, delineating the potential risks and benefits (and
alternatives) of the diagnostic and therapeutic strategy (77).
Changing practice patterns in medicine, including the
expansion of both managed care and for-profit physician
entrepreneurial ventures, have altered the relationships
among physicians, patients, and payers (79–81), creating
potential conflicts of interest for the physician in maintain-
ing the patient’s best interest. The availability of sophisti-
cated yet costly diagnostic and therapeutic technologies has
also created new challenges for physicians, who may now
serve simultaneously as physician, inventor, and investigator
of new therapies for vascular intervention. Government and
regulatory authorities now seek greater assurances that
physicians respect the best interest of the patient in their
clinical practice. Physicians who participate in clinical in-
vestigation must now report any real or perceived financial
“conflict of interest” with industry sponsors (81,82) as well
as with their academic institutions (76). Physicians who
have a direct conflict of interest should avoid being inves-
tigators of products for which they stand to gain financially,
except under extraordinary circumstances.
Ethical issues facing the cardiologist also involve the
performance of biomedical research. Patients are increas-
ingly seeking information about the competency of their
healthcare providers, often by reviewing “Best Practice”
listings provided by potentially conflicted third parties or
Internet sites created by hospitals who seek to attract new
patients into their healthcare system. Competency informa-
tion is rarely made available by organized medical societies
to the general public. A steady stream of new cardiovascular
training graduates in this country has also resulted in the
availability of an increasing number of physicians who
perform interventional procedures. A possible excess in the
number of interventionalists could also result in overutiliza-
Table 13. Suggested Minimal Room Sizes in the Cardiac
Catheterization Suite (5)
Use
Suggested Minimum
Size (sq ft)
Procedure room 500–600
Control room 150–200
Equipment room 100–120
Scrub facility (if independent from the procedure
room)
30
Holding room .120
Patient preparation room 120
Recovery room 120
Catheter and other storage room 100
Patient dressing room 70
Staff dressing room 70
Patient toilet 30
Staff toilet 30
Pharmacy space 30
Blood gas analysis 20
Staff lounge 70
Reception area 70
Film viewing area 70
Archival area (film and/or computerized archival) 70
Darkroom processing (or computer management) 70
Soiled utility 70
Janitorial space 20
Offices (space per office) 70
Conference room 120
Library 70
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tion of services, conflict of interest, and self-referral. Similar
issues exist with respect to the conduct of clinical research,
in which the patient may be encouraged to participate in
clinical protocols that may lead to little personal benefit (and
potential risks) by physicians who may have a direct or
indirect financial interest in their participation.
A. Operator Assistant’s Fees,
Sharing of Fees, Fee Splitting, and Fee Fixing
With continuing competition for patient referrals, there
is close scrutiny of the ethical (and financial) relationships
between the referring cardiologist or internist and the
interventional cardiologist. Although some procedures may
require the participation of two cardiologists (e.g., mitral
valvuloplasty or complex coronary or pediatric intervention),
it is not ethical for a cardiologist to charge an operator
assistant’s fee when he or she has not directly participated in
the procedure or when the cardiologist’s efforts were not
needed for the procedure. Furthermore, offering or provid-
ing a shared fee with another physician for the performance
of cardiac catheterization is unethical and potentially illegal.
It is also not ethical for a cardiologist to receive an
admission fee, referral fee, or other “kickback” or commis-
sion for admitting or referring a patient to a hospital or
cardiac catheterization facility (83). This principle applies
not only to fees, commissions, and compensations received
from other physicians and hospitals, but also to those
received from manufacturers of catheters, medications, in-
struments, devices, or supplies that may be used in the
catheterization laboratory (5). Collusion with any healthcare
provider may be unethical. Furthermore, such collusion may
be illegal when such arrangements involve Medicare funds
and are construed as inducement for referral (83). Collusion
with other cardiologists in an attempt to fix fees for
catheterization services may also violate antitrust laws (5).
B. Unnecessary Services
Without specific indications, “routine” right-heart cath-
eterization, pacemaker implantation during elective coro-
nary angioplasty, and simple coronary angioplasty in a
patient without ischemia may be unnecessary (83). A charge
to overread either hemodynamic data or angiograms by a
physician who has not performed the procedure is also an
unnecessary duplication of services and fees.
C. Self-Referral, Self-Ownership, and Self-Reporting
Changing relationships among hospitals, managed care
groups, and physicians have led to the development of
freestanding catheterization facilities that are not strictly
associated with hospitals but are owned instead by investors
or even physicians within a cardiovascular practice. Under
these circumstances, some practitioners may have financial
interests in diagnostic laboratories, including cardiac cath-
eterization facilities, radiological imaging centers, and am-
bulatory surgery centers (84). The investing physicians may
benefit financially from the referral of patients to these
facilities (79,80,84–87). Cardiologists must avoid any fi-
nancial business or industry arrangements that might influ-
ence their decision about the care of patients because of
personal gain (5).
Law in some states prohibits financial investments to
“self-referral” facilities (5,84). The national “federal physi-
cian self-referral law” (or “Stark Law”), however, explicitly
exempts cardiac catheterization. For other services desig-
nated in the Stark Law, physicians are allowed to personally
provide services in institutions in which they have direct or
indirect ownership or financial relationships. Referral of
patients to a catheterization laboratory facility (from which
the patient’s cardiologist collects earnings or shares in
profits) based solely on an effort to maintain volume
expectations, however, is a conflict of interest.
Direct remuneration from manufacturers for the use of
their devices, catheters or drugs may be illegal when the
patient is also charged for the use of the catheters or devices
or when governmental funds are used for payment (5).
Cardiologists should never engage in any practice that
would violate state or federal law regarding referral to a
facility in which they have financial interest. It is unethical
to refer patients to such a facility for financial gain alone.
The quality review process should be in place and enforced
to provide appropriate oversight to prevent these relation-
ships from becoming problematic. A second opinion from
another qualified cardiologist who has no fiscal connection
to the primary cardiologist or the catheterization laboratory
should be obtained if any questions arise about the appro-
priateness of a procedure being performed in such a facility.
Concerns have been raised about the accurate reporting of
individual operator and catheterization laboratory out-
comes. Local competition could result in the suppression of
clinical reporting of adverse events, and there may also be
pressure to maintain low costs and a low adverse event rate
to solicit institutional contracts with third-party payers.
Given the sensitive information related to individual oper-
ator success and complication rates, there may also be a
general reluctance to provide this information to potentially
nonobjective sources (91).
Physicians and hospitals should be encouraged to collect
procedural outcome information according to standardized
criteria such as those provided by the ACC and the SCA&I,
to compare these outcomes with “benchmark” standards
provided by the ACC and/or the SCA&I, and to subject
outcomes to peer review (91). These outcomes should be
risk-adjusted to account for complex patient subsets (e.g.,
cardiogenic shock and nonoperative candidates). The peer
review team should include individuals without a fiscal
interest in the laboratory and those not personally involved
in the procedures.
D. Informed Consent
Patient autonomy and, in many cases, the law mandate
that informed consent must be obtained before performance
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of any invasive diagnostic or therapeutic cardiovascular
procedures (77). If a physician extender (e.g., physician’s
assistant or nurse practitioner) or cardiology trainee is to
perform any part of a procedure, this should be stated
during the process of informed consent. Because the patient
and physician together determine the diagnostic and treat-
ment strategy, medical facts should be presented accurately
to the patient (and/or family or person responsible for the
patient’s care) at a level of communication that the patient
can easily understand (5). A discussion of the risks, benefits,
and alternatives should be undertaken in an unpressured
environment well before the procedure. It is recognized
that, on occasion, urgent situations may arise in the cathe-
terization laboratory, making it difficult to prepare the
patient for all possible emergency procedures. Particular
attention is needed for ad hoc interventional procedures
following cardiac catheterization in patients with a clear
indication for coronary revascularization. It is better to
explain the potential risks, benefits, and alternative therapies
to coronary intervention before administration of sedatives
or other agents that may affect the patient’s judgment at the
time of cardiac catheterization. Written informed consent
should be obtained and documented in the medical record
before the procedure.
E. Ethics of “Teaching”
Diagnostic and Therapeutic Procedures
Although “teaching” hospitals have been essential to
medical training for decades, patients admitted to a “teach-
ing” hospital have a right to be aware of the level of training
of the various physicians and related personnel involved in
their care. It is ethical for the cardiologist to delegate the
performance of certain aspects of the procedures to assis-
tants, such as physician’s assistants or fellows, providing that
this is done with the patient’s consent and under the
attending physician’s supervision (5). Fellows or physician’s
assistants, if qualified, can also perform certain invasive
procedures, provided that they are closely supervised at all
times by the attending cardiologist. It is not ethical to
delegate the entire responsibility of invasive procedures to
anyone not appropriately experienced in the performance of
the procedure.
F. Clinical Research Studies During
Diagnostic and Interventional Cardiac Catheterization
An increasing number of “teaching” and community
hospitals participate in clinical research protocols. Local
institutional review boards now require a higher standard of
disclosure for research studies than that required for clinical
practice (92). Accordingly, extra time should be taken with
patients asked to participate in clinical research to ensure
that all questions have been addressed. Research studies
should not increase the risk of major complications dispro-
portionally to the possible benefit when combined with
diagnostic catheterization and interventional procedures.
The investigative procedure should be performed after the
essential information has been obtained if possible, but only
if the patient’s condition is stable and the diagnostic
procedure has been performed in a timely fashion. Research
procedures performed during the catheterization must be
reviewed and approved by an institutional review committee
(83).
Safeguards for ensuring that patients are appropriately
enrolled in clinical research trials are as follows: that the
clinical investigator has thoroughly reviewed the protocol
for its scientific validity; the patient has met all the inclusion
criteria and none of the exclusion criteria; the patient has
been fully informed about the risks, benefits, and alternative
therapies; and the clinical investigator follows the clinical
protocol without unjustified deviation. In fact, most clinical
investigators are ethical individuals whose motivations are to
further scientific knowledge. Strict adherence to the clinical
protocol is the best assurance that conflicts of interest will be
minimized.
Through the difficult times facing physicians today, high
ethical standards, including maintenance of proficiency,
avoidance of real or perceived financial conflict of interest,
disclosure of potential conflicts, and, most important, main-
taining the patient’s best interest as primary, remain of
paramount importance. Only with attention to these issues
will our profession continue to be viewed by the public (and
our patients) as trustworthy and deserving of their respect.
VIII. IMAGING ISSUES
The primary technical focus in the cardiac catheterization
laboratory is the generation, recording, and display of
high-quality X-ray images during diagnostic and interven-
tional catheterization procedures. With greater numbers of
increasingly complex interventional procedures being per-
formed, acquisition of fluoroscopic and cineangiographic
images of the highest quality remains crucial for the optimal
performance of the catheterization laboratory. The ongoing
trend toward more complex interventional procedures re-
sults in greater exposure to radiation for the patient and
laboratory staff (93). The longer procedure times associated
with these procedures also place greater demands on the
X-ray generator and tube than may have been the case
previously. During the last half-decade, the prominent role
of 35-mm cine film as the recording and archiving medium
has been challenged, and cine-less operation has become
accepted as routine practice in many laboratories (94). The
movement toward digital technologies in the catheterization
laboratory and throughout the hospital and community
continues to change the interaction between the laboratory
and the outside world. The rapid evolution in information
technology in turn changes users’ expectations regarding the
accessibility of medical image data (95). These significant
technical changes require that the basic requirements in the
catheterization laboratory be revisited with some frequency
to ensure that the technical needs of the laboratory are being
met appropriately.
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A. Radiographic Equipment
The conflict between acquisition of high-quality angio-
graphic images and limiting X-ray exposure of patients and
staff has always been difficult to resolve satisfactorily. Car-
diac angiography, with its simultaneous requirements for
high acquisition rates and the need to visualize very small
objects, places some of the most severe demands on X-ray
generating equipment. Although there has always been
optimism that improvements in technology would help
resolve the conflict, the increasing clinical requirements
instead have led to yet greater demands on the equipment.
The wide acceptance of digital angiographic systems, which
have advantages in a variety of procedures, has led to new
challenges and concerns about issues of data rates, amounts,
and storage (96,97). High-quality video display has become
standard in the laboratory, and the use of pulsed-progressive
fluoroscopy is assumed with any currently available equip-
ment (98).
B. Generators
The rising proportion of interventional procedures per-
formed in the catheterization laboratory increases the de-
mands placed on the X-ray angiographic equipment, includ-
ing the X-ray generator. These requirements typically
include a high-frequency generator with outputs of 80 to
100 kW at X-ray pulse rates of 30 pulses per second (60
pulses per second for pediatric applications). The ability to
perform pulsed fluoroscopy and angiography with short
exposure times—sufficient to avoid motion blur of objects
moving at high speeds but still able to maintain a high
degree of contrast—has become a minimum requirement in
angiography. Modern equipment designed for the catheter-
ization laboratory should also have automatic exposure
control (AEC), which provides the optimal combination of
X-ray tube voltage, current, and exposure time most suited
for visualization of rapidly moving coronary arteries with
adequate contrast. Many laboratories choose to use the
high-level control (HLC) fluoroscopic technique, which can
produce exposure rates beyond the standard regulatory limit
of 10 roentgens per minute (R/min) but less than that used
during cineangiography. There are broader implications for
this higher exposure mode related to the resulting exposure
to the patient and staff, but if the capability is deemed a
requirement for a particular laboratory, a generator with
such capability will be required regardless.
C. X-Ray Tubes
Along with the high-output generator, the X-ray tube
used in cardiac catheterization laboratories—especially for
long, complex interventional procedures—must meet the
most demanding technical requirements (99). To visualize
the smallest coronary arteries and complex variations in
lumen geometry, focal spots of 0.6 to 0.8 mm are necessary.
To acquire multiple angiographic sequences lasting up to 10
to 30 s at rates of 30 fps (and higher), the tube must be able
to absorb large amounts of energy and dissipate the resulting
heat quickly to avoid delays between acquisitions—and
serious damage to the X-ray tube. Similarly, the extensive
fluoroscopic times required for interventional procedures
will be limited by the heat dissipation characteristics of the
X-ray tube. Heat storage capacities .1 million heat units
(HU) and even approaching 3 million HUs have been found
invaluable in the catheterization laboratory. A tube with
greater heat storage capacity provides several significant
advantages in the modern clinical environment: 1) it reduces
delays during clinical procedures if lengthy fluoroscopic and
angiographic exposures result in the heating of the tube to
its maximum capabilities; 2) it allows for penetration of
larger patients (or at steeper angulations) without resorting
to higher X-ray tube energies and the resulting reduction in
vessel (and device) contrast and increase in image noise; 3)
it provides the option for use of filtering materials that can
either reduce patient skin exposure, improve image noise
characteristics, or both.
D. Image Intensifiers
The performance characteristics of image intensifiers
used in the catheterization laboratory have improved con-
tinuously over the years. Higher conversion factors—greater
efficiency in light output as a function of X-ray input
exposure—along with improved contrast ratios and a reduc-
tion in geometric distortion have led to improved image
quality. As a result, image intensifier performance—in
dedicated cardiac catheterization systems—has been opti-
mized for the task of imaging the heart and coronary arteries
at the X-ray exposure levels used in that application. In
general terms, this translates to a high-contrast spatial
resolution .3.0 line pairs/mm at the entrance plane of the
image intensifier and acceptable signal-to-noise quality at
cineangiographic entrance exposures of 20 to 25 microR/
frame in the typical magnification mode used for coronary
angiography (100). On the other hand, systems optimized
for other imaging tasks, such as peripheral and vascular
angiography, cannot at the same time deliver the required
performance in the heart, and users should be aware that
there will be degradation in performance for the task of
imaging the heart and coronary arteries. The different X-ray
tube design, e.g., target size and angle, required for covering
a field of view corresponding to a 40-cm image intensifier
will not deliver the same results at the same X-ray exposure
for the 12- to 20-cm field of view customary in cardiac
imaging. Similarly, the light-gathering characteristics of the
larger image intensifier may compromise performance for
cardiac imaging at the smaller fields of view when only a
fraction of the intensifier input surface is used. In turn, there
are implications for the electrostatic optics within the
intensifier as well as for the light-gathering optics at the
output surface of the intensifier; in general, these effects will
degrade the image quality relative to an intensifier specifi-
cally designed for the cardiac application. In summary, the
effects that can occur in such a system are degradation in
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spatial resolution, increased image noise in fluoroscopy and
angiography, increased X-ray exposure rates, and delays due
to exceeding heat capacity for X-ray tubes.
E. Developments in X-Ray Detectors
As mentioned earlier, the image intensifier is a vital
component for X-ray angiographic imaging in the cardiac
catheterization laboratory, because no better alternatives
exist (to date) that can convert the X-ray intensity informa-
tion exiting the patient into usable, visible light information.
This visible light is converted to an electrical video signal
and in turn to a stream of numbers for subsequent process-
ing and storage. Recent developments in digital X-ray
detector technology demonstrate significant potential for
application in cardiac fluoroscopic and angiographic appli-
cations in the future. The first commercial systems have
only recently been introduced, and it is expected that they
will become more common; readers should thus be aware of
how these systems differ from those to which they have been
accustomed. The most significant difference between the
image intensifier–based imaging chain and those based on
digital detector technologies is that the entire image inten-
sifier tube will disappear, along with the video camera used
to convert the output light signal to an electronic voltage.
The promise is that this will deliver significant improve-
ments in spatial resolution because it will not be limited by
“blurring” processes inherent to the image intensifier sys-
tems, greater dynamic range and contrast resolution, and
because the new detectors are much simpler mechanically,
with less likelihood of failure and gradual degradation in
performance (101).
The candidate detectors that will most likely be appearing
in cardiac catheterization laboratories are digital “flat-panel”
detector systems that use a compact box in place of the
image intensifier tube to convert the incident X-ray signal
directly, essentially to an array of discrete electrical signals
that are read individually and processed, displayed, and
stored for further processing and review. These types of
detectors are characterized as direct digital because the
intensity values are generated as an array of digital values
(ones and zeros) at the detector without the need for
additional conversion processes that can add noise or de-
grade performance (102). These detectors have been made
possible by improvements and cost reductions in the man-
ufacture of flat-panel displays used in the computer industry
(e.g., laptop computer monitors). Essentially, these active
matrix arrays are combined with an X-ray–sensitive layer
that converts the X-ray signal to light incident on an array
of light-sensitive cells, anywhere from 1,000 3 1,000 to
2,000 3 2,000 cell arrays. Clinical testing of the first of
these devices has begun, and these detectors are now
becoming available as product options.
F. Video Components
1. Video Cameras. Along with image intensifiers, high-
quality video cameras have been an assumed component of
modern cardiac angiographic systems for generation of
high-quality images during fluoroscopy and to provide the
analog signal source for the conversion process used in all
current-generation digital angiographic systems. The tradi-
tional “pickup tube” camera, based on a scanning electron
beam to read off the spatially varying electrical signal
produced by the light output of the image intensifier, is well
understood and has been described in detail in the previous
guidelines (5). Modern systems use cameras that operate in
“standard” resolution mode (525 lines per video frame) as
well as “high” resolution mode (1,023 or 1,049 lines) for
both fluoroscopic and angiographic applications. An impor-
tant characteristic that should be carefully assessed in these
systems is the introduction of additional electronic noise to
the image in the higher-resolution modes requiring higher
bandwidth electronics. Another aspect related to the dis-
cussion of “dual-use” systems earlier relating to image
intensifier performance is the fact that video systems de-
signed for slow frame rate angiographic applications (typi-
cally at higher X-ray entrance exposures) may demonstrate
degraded temporal performance (i.e., blurring) when oper-
ated at the faster acquisition rates required for cardiac
imaging.
Although the pickup tube video camera has long been the
workhorse of cardiac angiographic systems, a relatively
recent development has been the increasing availability of
video cameras based on solid-state image sensors (e.g., the
CCD cameras) (103). Charged-coupled device sensors con-
sist of an array of discrete elements (typically 1,024 3 1,024)
that store the light information from the image intensifier
output until they are read by the camera electronics. Among
the advantages of the CCD camera are simpler design,
resulting in smaller size; improved dynamic range; improved
spatial resolution; absence of temporal lag; prolonged life;
lower cost and simplified maintenance requirements; and
lack of sensitivity to magnetic fields. (Note that the flat-
panel detectors described earlier also share a number of
these advantages.) The advantages listed earlier have been
extensively demonstrated and, in general, CCD cameras
operating at the same pixel resolution do offer better image
quality than video tube cameras. It should be understood,
however, that the use of CCDs in the detector chain does
not itself make this a direct digital detector. In most
applications, the output of the CCD camera is a time-
varying analog voltage signal that must be digitized before
use as with pickup tube cameras. One issue that should be
considered is the increased amount of data that can be
generated by the larger matrix sensors.
G. Digital Angiography Issues
Among the most significant changes in practice in the
cardiac catheterization laboratory in recent years has been
the consistent move away from 35-mm cine film as the
standard recording medium. In many laboratories in the
U.S. as well as abroad, cine film is no longer used in any
function of the catheterization laboratory. This has advan-
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tages that have been well documented (103,104), but there
are also a number of changes in the technical requirements
for a laboratory and considerations that must be made in
equipment purchase and use.
H. Effects on X-Ray Requirements
For many years, the promise of digital angiographic
recording has been accompanied by the promise of reduc-
tions in X-ray exposure (105). This has in turn led to
confusion when this reduction has not materialized as
digital angiographic systems are implemented. The image
quality in cardiac catheterization specifically at the exposure
per frame that is customarily found in this application is
primarily a function of the contrast signal and the image
noise that are found acceptable for the application. With
state-of-the-art equipment, the primary source of image
noise resides in the image intensifier, and this may be
objectionable. The light output of image intensifiers de-
signed for cardiac catheterization is more than enough at
standard entrance exposures for both cine film and digital
recording. Elimination of the cine camera does not by itself
mean that more light is available for the video chain; there
are already adequate amounts of light to obtain good video
signals. However, the noise is directly related to the statis-
tical properties of the relatively low X-ray beam flux
incident to the image intensifier. It is true that a digital-only
angiographic system allows more flexibility with the light-
limiting apertures in the video chain because one is not
limited by the requirements of delivering adequate light to
the cine camera. But the use of such apertures as a
dose-adjustment method is not routine. More practically,
the elimination of cine film does allow use of reduced frame
rate acquisition with the proportional reduction in X-ray
exposure (19). In the end, however, X-ray exposure per
frame is affected more by other factors, such as those
described earlier.
I. Digital Acquisition Requirements
As discussed earlier, at the time of this writing, essentially
every digital angiographic system requires a conversion from
an analog signal produced by a video camera to a string of
numbers stored and processed for display and analysis. The
spatial, contrast, and temporal resolution requirements for
cardiac catheterization are well understood and have been
met for the most part with digital systems operating at
matrix sizes of 512 3 512 pixels, bit depths of 8 bits
(corresponding to 256 intensity values), and acquisition
rates of 30 fps. With the ongoing reduction in the cost of
digital hardware, it has been possible to deliver improved
performance as well. Newer digital systems can record to
larger image matrices (1,024 3 1,024 is common) and
greater bit depths, with 10- and 12-bit images becoming
available. With pickup tube cameras, higher spatial resolu-
tion is a function of the camera scanning rate along with the
image intensifier magnification mode (and geometric mag-
nification). With CCD cameras, the size of the element on
the camera is necessarily fixed, but improvements in reso-
lution are still possible through the use of higher magnifi-
cation modes, which map a fixed-size element to a smaller
object in the patient. Similar factors apply as well to digital
detector technologies, but in that case, the resolution cannot
be improved through selection of a higher magnification
mode. In a field of view of 15 cm—typical for coronary
angiography—a 512 matrix results in a limiting resolution
of 0.20 to 0.25 mm (in the plane of the imaged object),
corresponding to a resolution of 2.0 to 2.5 lp/millimeter.
While this has been found in general to be adequate for
coronary imaging, it is less than the theoretical resolution of
cine film. Accordingly, many vendors are offering higher
resolution systems. In considering these systems, however, it
is important to ensure that the contrast resolution is
adequate as well. For instance, if there is insufficient contrast
from small objects due to other factors in the imaging
chain—X-ray energy, image intensifier or video issues, or
radiation scatter— the improved spatial resolution will be of
limited advantage. The issue of much greater data storage
requirements must be considered as well.
J. Digital Storage and Display
In most digital angiographic systems in use today, there is
limited storage capacity on the system itself, usually only
enough for one to several days’ worth of procedures. It is
therefore necessary to have a mechanism for medium- and
long-term storage. The development of the DICOM stan-
dard for cardiac angiography accelerated the use of digital
storage media by ensuring that there was a well-understood
method for exchanging digitally recorded procedures be-
tween laboratories and systems (106,107). Many laborato-
ries purchased the capability for storing exams on CD-
ROMs and have pursued that as a long-term storage
medium. Other laboratories have implemented automated
storage libraries, which provide access to many months or
years of procedures without the need for manual interven-
tion for retrieval and display. The specific archival systems
used by a laboratory should be selected on the basis of
clinical and financial considerations (96,97).
Whatever approach is taken, every laboratory should
ensure that the version of data retrieved from the archive at
some later date is identical to the version used for postpro-
cedure diagnosis and decision making. In most laboratories
the digital image data are typically not reintroduced into the
digital angiographic system for later review, but rather are
reviewed on a separate digital image review workstation.
This workstation can be supplied by either the original
X-ray equipment vendor or increasingly from a variety of
third-party manufacturers. The quality and cost of such
workstations can vary greatly. A laboratory should ensure
that review performance from media or over a network is
adequate for subsequent clinical assessment. Among the
factors that must be considered are display rates equivalent
to the original acquisition rate, full image display resolution,
image processing and enhancement, and sufficient exam
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storage capacity to avoid the need for delay in retrieval of
older exams. It should be noted that both the technology
and cost of imaging workstations are changing rapidly, and
a laboratory should anticipate future needs at the time of
equipment purchase.
K. Image Formats and Standards: The DICOM Standard
The acceptance of the DICOM standard for cardiac
angiography provided assurance that a version of an angio-
graphic exam exchanged with another laboratory or re-
viewed at a later date could be identical to that reviewed in
the laboratory during and immediately after a catheteriza-
tion procedure. It is unfortunately not always the case that
every vendor claiming to subscribe to the standard delivers
equipment that does in fact meet the functionality stated
earlier. The DICOM standard does include a conformance
mechanism by which a vendor is required to list the
capabilities and supported features of the product, but the
standard remains relatively new, and unfortunately, a labo-
ratory cannot rely solely on such claims. Any archiving,
exchange, or review system should be carefully assessed to
determine whether the exam data stored for local archiving
or written to media for exchange do in fact provide the same
quality of diagnostic information achieved in the original.
One factor that can ensure such equivalence is the use of
a direct digital interface between the angiographic acquisi-
tion system and the archiving or review system. Due to the
relatively recent introduction of the standard and the fact
that there is a large installed base of equipment of varying
age, this digital interface is achieved through a range of
sometimes complicated approaches or, for some of the
oldest equipment, cannot be achieved at all.
Newer digital angiography equipment is available with a
DICOM network interface, meaning that the exam infor-
mation leaving the system is already formatted according to
the DICOM standard. This has two advantages: 1) data
equivalence is assured and 2) any receiving system that
supports this interface can be used for storage and review
(i.e., a laboratory has more choices). An alternative ap-
proach typically used with older equipment is a digital
interface, which requires an additional step to format exam
data to the DICOM standard. This approach can work as
well, but it requires that the developer of the interface,
usually the manufacturer of the X-ray system, make the
interface specification available to other vendors. Otherwise,
only equipment from the original vendor will support the
interface. Again, it should be noted that either type of
interface will usually work, but it should be understood from
the onset which type is being provided.
Another alternative that has also been implemented,
especially with older equipment, is an analog capture inter-
face rather than a digital interface. In this approach, the
analog video signal is captured and digitized somewhere in
the acquisition or display chain, and this second digital
version is then formatted according to the DICOM stan-
dard and used for archiving, display, and exchange. Labo-
ratories should be cautioned that the image data resulting
from this approach is not strictly equivalent to the informa-
tion available at the time of the procedure. With appropriate
precautions, the quality can still be quite high, but, in many
cases there is significant degradation in image quality. In the
case of older equipment for which no alternative exists, this
approach does provide a digital archive and exchange
approach of nearly equivalent image quality, but only if the
parallel image capture is performed to a specification close
to that incorporated within the original X-ray vendor’s
analog-to-digital conversion. In some cases, irreversible data
compression is also used during the capture process to save
costs and improve performance, but this leads to artifacts in
the stored archival copy, which degrade image quality and
can affect visualization of the anatomy.
L. Digital Image Resolution
As discussed earlier, digital cardiac angiographic systems
have most often incorporated digital resolutions of 512 lines
by 512 columns by 8 bits per sample—usually together with
acquisition rates of 30 fps. The initial basic version of the
DICOM standard for digital cardiac angiography supported
only this format to provide at least one format that many
vendors could support. In recent years the number of cardiac
angiographic systems available at higher resolutions has
increased, and the issue of digital equivalence between the
acquired exam information and the stored and exchanged
versions has emerged. The issues include the clinical re-
quirement for the higher resolution and whether the per-
manently stored copy should also be stored with the higher
resolution. In general, a matrix size of 512 3 512 has been
deemed acceptable for clinical applications despite the fact
that this corresponds to a minimum spatial resolution on the
order of 0.2 to 0.3 mm.
For some applications, such as quantitative coronary
angiography of complex stenoses, higher resolution (e.g.,
0.1 to 0.15 mm) is seen as optimal (100). In that case, the
1,024 3 1,024 matrix size will deliver improved resolution
but at the cost of increased data acquisition, storage, and
transmission requirements. Under these circumstances, the
version of the exam stored locally as well as used for
exchange should accommodate the higher resolution images
on which the clinical diagnosis was made. The DICOM
standard does accommodate these higher image matrices,
but a laboratory should ensure that the equipment pur-
chased for this application does indeed store all the acquired
information and can write exchange media in the larger
format (assuming that the receiving laboratory in turn has
the ability to display the larger format images). Similar
concerns apply to network transfer, which will require
greater bandwidth capacity for the larger amounts of data
or, alternatively, greater delays in transmission.
M. Data Compression
Despite the rapid improvements in digital storage and
transmission technology, the data requirements of digital
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cardiac angiography remain among the most demanding in
medical imaging. As a result, some equipment vendors and
suppliers of imaging applications have sought to reduce the
amount of data through the use of mathematical techniques
or compression methods (108). Some compression methods
are completely reversible or lossless, and in the end the
recipient or user has precisely the same equivalent data that
were available initially. In contrast, irreversible or lossy
compression methods reduce the amount of data, but the
resulting image information is not strictly identical to the
original angiographic information. The variation that can be
detected visually and the effect it may have on clinical
assessments made from the images depends on the type of
compression method and degree of reduction. Lossy com-
pression methods can result in much greater amounts of
data reduction, but the resulting images may contain de-
tectable artifacts that were not in the original image. The
basic problem with the use of irreversible compression
methods is that a user at a later time is not provided with the
same information used initially; this may be acceptable in
some applications, but none in which the original informa-
tion is no longer available if needed. The ACC and the
European Society of Cardiology have sponsored a multi-
center clinical study to assess the effects of one of the more
common compression methods (motion JPEG) on critical
diagnostic tasks. The results of that study indicate that as
the amount of compression is increased, the ability to detect
clinical features is impaired. It is strongly suggested that
laboratories avoid the use of lossy compression methods for
the permanent storage of digital angiographic data (109).
N. Telemedicine Applications
Routine storage and availability of angiographic records
in a digital format makes possible a new class of clinical
applications, which fall under the general category of tele-
medicine—referring to the electronic transmission of clini-
cal image data over large distances to support clinical
decision making at remote sites (110). In addition to the
digital format of the procedure data in the acquiring
laboratory, this requires an accepted standard format for the
image data that can be displayed at the receiving site as well
as a reliable digital network link between the sending and
receiving centers. Such Wide Area Network (WAN) appli-
cations extend, in simplest terms, the network from within
a laboratory or hospital to much greater distances. The
network in effect provides a user hundreds of miles away
with the ability to display and review the procedure image
data as if he or she were in the procedure laboratory.
In one example of this type of application, simple “store
and forward” transmission of a procedure from a referring
hospital to another medical center may be performed, in
effect replacing the mail or courier service with electronic
transfer. One advantage of this approach is that the original
copy of the exam record remains in the acquiring laboratory.
At the other end of the spectrum, “expert” physicians at one
center can participate in and provide advisory support in real
time for a procedure being performed at another center.
Although the cost of digital network transmission is
being reduced and networks are being extended to more
locations, the bandwidth needed to transmit cardiac cathe-
terization examination results rapidly and completely re-
mains costly and/or relatively rare at this time. As with
many networking applications, users must choose between
speed and expense. As a result, some attempts to provide
telemedicine services for catheterization procedures in a less
costly manner have incorporated data compression methods
to reduce the size of the data files being transmitted and, in
turn, reduce the time required to transmit the files. As with
the issues raised in the discussion earlier, this means that the
data being reviewed at the distant location may differ to a
clinically relevant degree from the data used in the initial
review and diagnosis. There may be applications for which
this is acceptable, but laboratories and hospitals should not
use such systems for an application that involves decision
making solely on the basis of compressed images, which are
degraded in diagnostic quality. Specifically, systems devel-
oped for routine video conferencing over standard telephone
lines do not as a rule have adequate image quality for
transmission of clinical image data acquired under the
conditions required for cardiac angiography. Similar con-
cerns apply to transmission over the Internet using standard
networks. There are technical means available to deliver
diagnostic image quality of digital angiograms in a timely
fashion; laboratories considering a telemedicine application
should examine the technical specifications of such systems
carefully. In the near future, clarification of privacy concerns
for individual patients should allow for discussions of
patient cases without jeopardizing patients’ confidentiality.
O. Quantitative Measurement Methods
With increasing storage and easy access to catheterization
results in a digital format, the use of computerized methods
to measure coronary artery stenosis severity, left ventricular
function, regional wall motion, and other techniques be-
comes much more feasible (111,112). These methods pro-
vide objective, reproducible measures for assessment of
disease and physiological function and are available for use
in all laboratories rather than being limited to multicenter
clinical trials. Laboratories should ensure that systems being
used have been fully validated in well documented in vitro
and in vivo studies and that technicians are familiar with the
procedures necessary to produce measurements that are
reliable, accurate, and reproducible. With the elimination of
cine film and its replacement with digital images that are
readily accessible, one of the greatest sources of variability is
no longer an issue with the elimination of the need to
convert cine film to a digital file. Consistent procedures
must be followed, and it is important that the analysis be
performed on the original image data acquired at the time of
the procedure. As mentioned earlier, systems are available
that store and exchange versions of the images that differ
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significantly from the original acquired data; in general,
results on such secondary capture images or, possibly,
compressed images will not be as reliable.
P. Further Developments in the DICOM Standard
Just as the DICOM standard for digital images made it
possible for catheterization laboratories to routinely ex-
change high-quality digital images, other developments are
under way to enable similar standardized formats for other
types of information gathered during catheterization proce-
dures (113). An outgrowth of the DICOM effort extends
the standard format to include physiological data: hemody-
namic and electrocardiographic waveforms and measure-
ment results. The primary focus of the effort was to facilitate
a “unit patient record” for the catheterization procedure that
includes all information necessary as a local record and for
interchange between laboratories and hospitals. Although
the standard is in a preliminary stage at this time, newer
versions of imaging and waveform recording equipment will
support the standard, and laboratories that wish to incor-
porate such capabilities should obtain assurance that all
required equipment supports the standard. In a related
development, standard formats can ensure that the results of
the procedure data can be exported electronically in a format
compatible with national data registries such as the ACC
NCDR (114). Other developments include the integration
of other imaging modalities such as intravascular ultra-
sound, as well as standard formats for clinical reports that
can be transmitted electronically in such a manner that they
can be displayed in other laboratories regardless of which
vendor’s equipment was used to generate the original
procedure report.
IX. RADIATION SAFETY ISSUES
Two recent reviews of radiation safety in the cardiac
catheterization laboratory outline in detail many of the
major issues (93,115,116). The National Council on Radi-
ation Protection and Measurement (NCRPM) provides
radiation exposure guidelines for medical workers. There is
no threshold below which harmful effects may not occur.
The use of ALARA—“as low as reasonably achievable”—
doses of radiation should always be considered. A recent
membership survey performed by the Ad Hoc Committee
on Women in Cardiology sponsored by the ACC indicated
that concerns surrounding exposure to X-rays was a leading
factor in the decision of both men and women to avoid
interventional cardiology as a profession (93).
A. Terms for Understanding Radiation
Exposure in the Cardiac Catheterization Laboratory
In the cardiac catheterization laboratory, ionizing radia-
tion is produced by the interaction of X-rays and matter.
The basic units of measurement are summarized below (93).
The measure of exposure is the roentgen (R). The roentgen
is a unit of radiation exposure defined by noting the amount
of ionization per mass of air due to X-rays or gamma rays.
It is described in terms of coulombs per kg (C/kg).
The amount of energy absorbed per unit mass of material
is defined by the rad (radiation absorbed dose). It is
described in terms of gray units (Gy), in which 1 Gy 5 100
rad.
The amount of energy absorbed by different materials for
the same exposure can vary depending on the type of
radiation and the atomic number of the material absorbing
the radiation. In radiation protection this is expressed in
terms of the rem. A rem is basically a rad multiplied by some
quality factor. In cardiology the quality factor of X-rays and
gamma rays is 1. Therefore, 1 rem 5 1 rad. The units for
rems are expressed in terms of sieverts (Sv). There are 100
rems in 1 Sv. Because radiation effects are often expressed in
mSv; there are 10 mSv/rem.
B. Biological Risks From Radiation Exposure
The biological risks from radiation exposure depend on
the amount of energy absorbed and whether there is injury
to the DNA or the cell itself. A stochastic effect is an
all-or-none effect that results in DNA injury. This can lead
to an increased risk of cancer or other genetic effects.
Stochastic effects occur with increasing frequency as the
cumulative radiation exposure increases, but once the injury
has occurred, a further increase in the dose for that cell does
not change the injury afflicted. Nonstochastic effects, also
referred to as deterministic effects, are dose dependent and
result in cell death. Erythema, desquamation, cataracts,
marrow suppression, organ atrophy, gonadal injury, sterility,
and fibrosis are clinical expressions of this type of injury.
The greater the radiation exposure, the greater the amount
of injury that occurs with nonstochastic or deterministic
injury.
Table 14 summarizes current recommendations and con-
cerns. The average background exposure that may be ex-
pected is about 0.1 rem/year. During an average interven-
tional cardiac catheterization procedure, the physician
operator receives about 0.004 to 0.016 rem of exposure
(117–120). In 1 review, the operating physicians in the
cardiac catheterization laboratory received from 0.2 to 6.0
rems/year, the nurses received from 0.8 to 1.6 rem/year and
Table 14. Pertinent Radiation Exposure Recommendations
and Concerns
Average background radiation exposure 0.1 rem/year
Average operator exposure per
interventional cardiac catheterization
0.004–0.016 rem
Maximum annual recommended exposure
for medical workers
5 rem/year
Maximum lifetime accumulated exposure
for medical workers
1 rem 3 age (in years)
or 50 rem
Maximum fetal exposure 0.05 rem/month or 0.5
rem total
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the technologists about 0.2 rem/year, as documented by
collar and waist badges (120). Ancillary personnel in the
cardiac catheterization laboratory thus receive about 10% to
30% of the dose received by the primary operator. The
maximum allowable occupational exposure from all sources
for medical workers is 5 rems/year for the whole body. Over
a total career, no one should receive a cumulative exposure
.1 rem 3 age (or 50 rems) (93).
The cancer risk from radiation exposure is a stochastic
effect and appears to be related to the lifetime cumulative
dosage received. The risk of fatal cancer increases by about
0.04% 3 rem of lifetime exposure (121). The estimated risk
of fatal cancer in the U.S. is about 20% (122). If a busy
interventional cardiologist receives about 3 rems/year and
practices for 25 years, the total dose received would be 75
rems. This would translate into an added risk of fatal cancer
of 75 3 0.04% or 3%, resulting in a total projected overall
lifetime risk of 23% for development of a fatal cancer.
Radiation exposure of the fetus in the pregnant worker is
a special case that deserves comment. It is permissible for a
pregnant worker to make a decision as to whether to
continue working in the cardiac catheterization laboratory
during her pregnancy. There must be no repercussions
whether or not a pregnant worker chooses to work in the
laboratory itself (93). Appropriate protection and monitor-
ing must be provided. The United Nations Scientific Com-
mittee on the Effects of Atomic Radiation (UNSCEAR)
estimates that the risk of a congenital malformation or of
developing a malignancy after in utero exposure of 1 rem is
about 0.2% (123). Fetal exposure to high doses of radiation
between weeks 8 and 15 may also result in mental retarda-
tion, as determined from Japanese survivors of the atomic
bomb. The risk of mental retardation in this instance is
about 0.4%/rem of exposure (121). On the basis of these
data, it is recommended that fetal exposure to radiation, as
monitored by a waist dosimeter worn under the outer lead
apron, should be no more than 0.5 rem for the entire
pregnancy or ,0.05 rem/month (93). This can be accom-
plished through careful attention to radiation dose exposure.
The greatest concern about the nonstochastic effect of
long-term occupational exposure is the formation of cata-
racts. The risk is small, but cataracts have been associated
with single doses in the range of 200 rads (124). Cumulative
doses of up to 750 rads have also been reported, with no
evidence for cataracts (124). Cataracts usually form after a
latent period of several years. The recommended maximum
exposure to the eye lens is 15 rems/year. Eye protection is
therefore warranted. Leaded eyeglasses help reduce the
exposure risk.
C. Measuring Radiation Exposure
Radiation exposure is commonly measured by one of two
methods, either a film badge or a transluminescent dosim-
eter (TLD) badge. The film badge basically contains a piece
of X-ray film. The magnitude of exposure to X-rays is
derived based on the density of the exposed photographic
film within the badge compared with densities from film
that has had known amounts of exposure. The TLD badge
contains a disk with lithium fluoride crystals. The lithium
fluoride crystal absorbs the X-rays, raising the electrons to a
higher state. When heated, the electrons in the crystal
return to their baseline state, releasing light in proportion to
the X-ray exposure.
Proper measurement of radiation exposure requires the
dosimeter badge to be worn with the front of the badge in
the direct line of the scattered X-rays. If a single badge is
worn, it is usually placed on the thyroid collar. It is
recommended, however, that two badges be worn during all
cardiac catheterizations, with the second badge placed under
the protective lead at the waist (93). Cardiac angiographers
receive the highest exposure on the hands, but these are not
usually monitored because of sterility issues with wearing a
ring badge. When a ring badge is worn, it should be placed
with the label (the TLD chip) palm side down (93).
D. Minimizing Occupational Exposure
The three tenets for reducing occupational exposure to
radiation are time, distance, and barriers. X-ray scatter is
also reduced by minimizing the number of magnified views,
using digital-only cine acquisition, keeping the image in-
tensifier as close to the patient as possible, and selecting the
highest kVp that will provide acceptable image contrast.
Obviously, reducing the time of exposure results in a
reduction in overall radiation exposure. Scatter exposure is
reduced by using lower framing rates and pulsed fluoroscopy
and by minimizing both fluoroscopic and cine time. Al-
though fluoroscopic radiation may result in 1/10 or so of the
exposure per sec compared to cine, the far greater duration
of fluoroscopic use during procedures in the cardiac cathe-
terization laboratory can result in a 6-fold greater radiation
exposure from fluoroscopy than from cine for many inter-
ventional procedures (125). The radiation beam attenuates
based on the inverse square law (1/d2), and distance be-
comes an important means of reducing operator radiation
exposure from scatter radiation. Most X-ray scatter occurs at
the entry surface of the patient. The nearer the operator is
to the X-ray tube (not image intensifier), the greater the
X-ray exposure. For instance, in the cranial LAO view,
where the operator is closest to the X-ray tube and the
bottom of the table, the operator exposure may be 2.6 to 6.1
times that observed in the caudal RAO view, where the
X-ray tube is on the other side of the table (125). Finally,
barriers are important. Proper collimation of the X-ray
beam and copper filters helps reduce exposure from the
source. Shielding such as side table drapes, properly posi-
tioned door- or ceiling-mounted acrylic shields, lead aprons,
thyroid collars, and protective eyeglasses are all important in
limiting occupational radiation exposure.
E. Minimizing Radiation Exposure to the Patient
Radiation to the patient can be minimized by some
simple rules. Some of the same concepts apply here as noted
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earlier for reducing exposure to the medical worker. Because
the patient is directly in the X-ray beam, the patient benefits
primarily from measures that reduce X-ray dose. These
include collimation of the X-ray beam, use of pulsed
fluoroscopy, copper filters, digital-only cine acquisition,
limiting magnified views, reduction of fluoroscopy and cine
times and framing rates, keeping the source-to-image dis-
tances as narrow as possible, using the highest kVP accept-
able to maintain the lowest mA possible, and direct shield-
ing of sensitive areas, such as the gonadal regions.
F. Quality Management
Quality management in the catheterization laboratory
must include: 1) an effective and ongoing educational
program in the diagnostic use of X-rays, 2) accurate mon-
itoring and timely reporting of personnel exposure, and 3)
modification of procedural conduct in those cases where
exposure levels are of concern. These issues are addressed
earlier in this document (see QA Issues in the Cardiac
Catheterization Laboratory).
X. SPECIAL CONCERNS FOR THE
PEDIATRIC CARDIAC CATHETERIZATION LABORATORY
The Pediatric Cardiac Catheterization Laboratory (PCCL)
presents several challenges and differences not faced by the
adult invasive cardiovascular specialist. The following is a
general overview of these issues.
A. Differences in Goals
The PCCL should function as an element within a
pediatric cardiovascular center or program. The overall goal
of such a center or program should be to provide both
comprehensive diagnostic services and a full range of treat-
ments, interventions, and surgeries needed to provide high-
quality pediatric cardiovascular care. Within the center or
programmatic context, the goal of a PCCL is to perform a
range of cardiac catheterizations in children with congenital
or acquired heart disease and in adults with congenital heart
disease. Unlike in adult cardiology, the usual case is that the
heart internal structure is abnormal. Diagnostic catheteriza-
tion may include quantitation of cardiac index, and calcu-
lations of left-to-right and right-to-left shunts and pulmo-
nary vascular resistance are more often required. Right- and
left-heart catheterization is the norm rather than the excep-
tion. Measurement of cardiac index by thermodilution is
possible when there are no shunts, but measurement or
assumption of oxygen consumption for Fick shunt determi-
nations is more commonly performed. Because of periods of
rapid growth in infancy and childhood and the need for
comparison of data across sizes of patients or over time in
the same person, output and resistance values are indexed or
corrected for body surface area in pediatric cardiology.
Furthermore, pediatric angiographic studies have goals that
include defining and displaying intracardiac anatomy in a
projection-type medium to complement the planar media of
echocardiography and magnetic resonance or computerized
tomographic imaging. A wide variety of congenital and
acquired defects are investigated in the PCCL.
Pediatric interventional procedures are a primary or
secondary objective in approximately half of all PCCL
catheterizations. A wide range of unique interventional
procedures is now possible. These procedures include bal-
loon atrial septostomy, blade or balloon dilation atrial
septostomy, valve and vessel dilation, stent implantation,
patent ductus arteriosus and other vascular closure, endo-
myocardial biopsy, foreign-body retrieval, and the full range
of electrophysiological procedures. Special expertise in pe-
diatric patients is gained in these procedures during pedi-
atric cardiology fellowship training and in pediatric cardi-
ology postfellowship training in the interventional cardiac
catheterization laboratory (often during an additional train-
ing year). PCCLs that routinely perform pediatric trans-
catheter interventional procedures should exist only in
clinical environments where pediatric intensive care and
pediatric cardiovascular surgery are available.
Sedation is an important function in the PCCL, where
patients cannot be calmed or reassured without medication
or even assumed to be able to remain on the procedure
“bed.” The pediatric cardiologist assumes responsibility for
the safe conscious sedation of the patient, and the impor-
tance of monitoring is no different from that described
earlier for adults receiving sedation.
B. Who Should Perform
Catheterization in Adult Congenital Heart Disease?
Pediatric cardiac catheterization laboratories, whether
dedicated or shared with adult cardiologists, should have a
pediatric director. The director should be board certified in
pediatric cardiology and should have additional training in
pediatric cardiac catheterization and intervention (or qual-
ifying experience). The director should be responsible for all
aspects of the administration and function of the PCCL
(including backup of other pediatric operators with less
training or experience). In addition, QA and QI activities
related to pediatric studies should fall under the director’s
guidance.
Other than the PCCL director, attending physicians who
perform cardiac catheterization in children are generally
board eligible or board certified by the American Board of
Pediatrics, Subspecialty Board of Cardiology. There may be
exceptional cases in which a competent physician has gained
extensive experience without formal board certification, but
these physicians usually have been allowed privileges by a
“grandparent” clause. Whether privileges for non–board-
eligible physicians should be granted is left to the discretion
of the individuals involved and the hospital credentialing
process.
Although it is recognized that the definition of the
“pediatric” age range is somewhat variable, it usually encom-
passes the period from birth through 18 (or 21) years of age.
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It is recommended that for patients under the age of 18
years who require cardiac catheterization for congenital
cardiac problems, the procedure should be performed by a
pediatric cardiologist. Adult patients with previously diag-
nosed (repaired or unrepaired) congenital heart disease or
with native congenital heart problems requiring cardiac
catheterization should have the procedure performed: 1) by
a pediatric cardiologist, 2) by an adult cardiologist and a
pediatric cardiologist collaborating during the procedure
(with one or both scrubbed), or 3) by an adult cardiologist
with an established special interest and expertise in adult
congenital heart disease. Adult cardiologists with little
experience in congenital heart disease should not perform
cardiac catheterization in patients with congenital cardiac
problems.
C. QA Issues
Representative complication rates for pediatric cardiac
catheterizations are available from a number of reviews. A
recent study of complications in 4,952 consecutive pediatric
catheterization procedures found an overall complication
rate of 8.8%, with a major complication rate of 2.06% and a
death rate of 0.14% (126). A higher risk for complications
was present in patients who were younger and in those
undergoing interventional procedures. Fellows et al (127),
noted that the rate of complications for therapeutic catheter
procedures depended primarily on the type of intervention.
In that study, the rate of complications for aortic valve
stenosis dilation was 10 times that for recurrent coarctation
treatment. The Valvuloplasty and Angioplasty in Congen-
ital Anomalies (VACA) study group (128) reinforced this
finding in 1990 in its series of articles concerning various
types of interventional catheterizations. These complication
rates might be expected to improve because of advances in
catheter technology and techniques. However, the increas-
ing percentage of interventional cases and postoperative
catheterizations in smaller and smaller children may hold
the complication rates at current levels. A center’s
catheterization-related mortality should be ,1%, and death
should be extremely rare outside of neonatal and high-risk
interventional cases. In addition, major complications (po-
tentially life-threatening events) should occur in ,2% of
cases (126). In radiofrequency ablation procedures, the
incidence of permanent complete atrioventricular block
should be #2% (129).
Informed consent in the PCCL is usually obtained from
the patient’s parents or guardians. This consent includes the
physician’s (or his or her designees, such as the cardiovas-
cular fellows) explanation of the risks, benefits, and alter-
natives related to the procedure, with documentation of the
explanation and of the parent/guardian understanding
shown by a signature. In urgent or emergent cases, such as
when a transferred patient requires emergency balloon
septostomy and the parents are in transit, consent may be
obtained by telephone or even assumed and the procedure
performed. The Committee recognizes that there are con-
sent and assent procedures and guidelines that vary by
jurisdiction (hospital, state, county) and defers to those
where applicable. Age or other circumstances that afford
competence to the patient vary as well. These will determine
whether it is acceptable to obtain the patient’s “assent” or
whether formal consent is required.
D. Inpatient Versus Outpatient Setting for Procedures
Although outpatient procedures have become common in
the PCCL, there is less uniformity in patient and parent
suitability for hospital discharge shortly after catheterization
than in adult patients. Infants and young children cannot be
instructed or expected to remain still without moving their
legs for a period after a procedure. Any volume of blood lost
into the subcutaneous tissue or retroperitoneum or onto the
bandage or bedclothes will have more significance if the
patient is smaller. In general, patients and their parents may
have to travel farther for treatment at a PCCL than at an
adult catheterization laboratory. The patient may also be
farther from appropriate medical attention after returning
home. Despite the smaller size of the patient, the sheath
sizes used in pediatrics may be nearly the same size (5F to
8F) as those used in adults. For these reasons, it is suggested
that overnight observation be anticipated and allowed
whenever there is any concern about patient safety.
Nonetheless, a set of written criteria should be established
for same-day catheterization and discharge by each PCCL.
These criteria would account for differences in procedure
type, patient age and expected compliance, parent or guard-
ian reliability, travel distance, procedure duration and time
of completion, and the cardiac physiology in determining
which patients are eligible for discharge on the day of
catheterization. These guidelines should establish discharge
criteria such as absence of bleeding, presence and adequacy
of pulses and perfusion, access to medical evaluation and
care after discharge, and parental understanding and ability
to observe overnight.
E. Operator and Laboratory Volume
If a PCCL routinely performs ,75 cardiac catheteriza-
tions/year, consideration should be given to whether the
volume justifies the program. Although the Committee
recognizes that access to services is important, there is also
the valid impression that a minimum experience is required
for the cardiologist and staff to maintain proficiency. In the
previous ACC/AHA guidelines (5), the pediatric caseload
for an individual was estimated at 50 to 100 cases/year. In
the 1991 American Academy of Pediatrics guidelines (130),
it is recommended that a minimum of 1 to 2 catheteriza-
tions be performed/week to maintain skills. Thus, for a
single cardiologist, the minimum number of cases is still
thought to be 50/year. Because, as noted, the level of skill
and expertise required and the complication rates experi-
enced are related to the type of intervention, credentialing
for therapeutic cardiac catheterization should be procedure
specific (131).
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A number of considerations must be taken into account
when a decision is made regarding the minimum number of
cardiac catheterizations that should be performed by a
pediatric cardiologist or a PCCL. Importantly, although
there are ample data regarding adult interventional proce-
dures, there are no data relating number of pediatric
procedures to skill or outcomes. It is important that insti-
tutional, local, and personal factors be weighed.
QA plans must be in effect in all PCCLs to monitor
outcomes of cardiac catheterization. There are some simi-
larities and differences between the strategy required for QA
in the PCCL versus the adult cardiac catheterization labo-
ratory. For example, there is not a prior acceptable rate of
normal cardiac catheterizations. In patients undergoing
cardiac catheterization for hemodynamic reasons or possible
intervention, the rate of normal should be zero. Any number
of patients may have electrophysiological abnormalities or
acquired disease with structurally normal hearts but abnor-
mal physiology, and these would not be considered to be in
the “normal” group. The effort to operate within the
published complication rates is the same in all laboratories,
although the types and rates of complications in the PCCL
are different from those in the adult laboratory. Although
intervention procedures are usually planned well in advance,
ad hoc procedures might well be required. Such procedures
as coil occlusion of a ductus arteriosus or aortopulmonary
collateral or balloon dilation with or without stent place-
ment may be needed even when not previously planned.
Diagnostic quality and accuracy of catheterizations and
procedural outcomes should be examined, with each PCCL
responsible for earmarking certain indicators and examining
them with plans for improvement if warranted by the data.
F. Procedural Issues
1. Premedication. The choice, dose, timing, route, and
overall use of premedication varies widely with age, size, and
condition of patient and the experience and training of the
operator. There is no “standard” premedication. Chloral
hydrate, diphenhydramine (Benadrylt), and diazepam (Va-
liumt) are frequently given orally for sedation. Intrave-
nously, midazolam (Versedt), morphine, fentanyl, hydro-
morphone (Dilaudidt), and other medicines can be used to
good effect. The advantages of midazolam are that it can be
given by continuous infusion and it can be reversed if
necessary. Reversal of midazolam with flumazenil (Roma-
zicont) does not usually precipitate the severe discomfort
and agitation seen with naloxone (Narcant) narcotic antag-
onism. Ketamine may be used in small intramuscular or IV
bolus doses for rapid-onset anesthesia. This may help
during precise intervention when patient movement might
be detrimental to procedure success. Meperidine (De-
merolt) alone or in combination with promethazine (Phen-
ergant) is sometimes used intravenously or by the intramus-
cular route for analgesia and sedation. Chlorpromazine
(Thorazinet) is used less often than previously, because of
the availability of and experience with other medicines.
2. Vascular Access Issues. Techniques for venous and
arterial access are similar for children and adults. In young
children with congenital heart disease, however, much (or
all) of the catheterization can often be done from the venous
approach. Therefore, there is a greater opportunity for
placement of a small cannula in the artery at the beginning
of a procedure (rather than the larger sheath). This allows
monitoring of blood pressure and sampling of blood gases
without the arterial trauma that might be caused by the
sheath. If and when the need for retrograde heart catheter-
ization arises, the area around the artery may then be
re-anesthetized and the small cannula changed for the
appropriate-sized arterial sheath. The transseptal procedure
is frequently used for access to the left atrium. Properly
performed, this approach does not add significantly to the
incidence of complications. It is an important technique for
radiofrequency ablation, mitral valve stenosis investigation
and valve dilation, prosthetic aortic or mitral valve assess-
ment, and many other catheterization functions. Because of
the frequency of venous catheterizations and indwelling
femoral venous lines in neonates and infants, limited or
absent venous access from the femoral veins is not uncom-
mon. Therefore, venous access from the internal jugular,
subclavian, or even basilic approaches is frequent. More
recently, the transhepatic approach has been used very
successfully for both diagnostic and interventional proce-
dures.
The use of heparin in the flush solutions is routine, but
the additional use of bolus-dose heparin depends on the
patient’s ACT, procedure type, and vascular approach. It
would be usual, for example, not to use bolus heparin for a
right-heart catheterization or the prograde right and left-
heart catheterization, but heparin would be used in aortic
valve dilation. At the end of a procedure an ACT may be
checked and if necessary the heparin effect reversed with
administration of protamine sulfate in much the same
manner as described earlier for adults. Mechanical plugs or
compression devices are rarely used in the PCCL because of
the small vessel size. Hemostasis is almost always achievable
by direct manual pressure followed by placement of an
adhesive or elastic tape over a gauze pad on the access site.
3. Medications Used During the Procedure and Use of
Anesthesia. Medications used during the procedures in the
PCCL are essentially the same as those noted earlier for
premedication. Repeated bolus doses of sedatives may be
used, and/or a continuous infusion of midazolam or other
drug may be instituted. It is necessary that a nurse or
physician assess and document the patient’s condition after
each bolus dose of sedative according to the institution’s
conscious-sedation guidelines. It may be useful to consider
turning a continuous infusion down or off after the last
angiogram or pressure measurement to allow the sedation to
begin wearing off as hemostasis is achieved. Systemic arterial
oxygen saturation should be continuously monitored by
pulse oximetry.
General anesthesia is performed by an anesthesiologist or
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trained nurse anesthetist under the supervision of the
anesthesiologist. Possible indications for anesthesia consul-
tation include patient considerations and procedure charac-
teristics. For example, a developmentally delayed teenager
who is fearful may be unable to be sedated without general
anesthesia. Patients who are critically ill or in pain will
benefit from anesthesia. Prolonged procedures such as
radiofrequency ablation or those that require transesopha-
geal echocardiography may be greatly facilitated with gen-
eral anesthesia. Certain interventional procedures such as
aortic or mitral valve dilation, atrial septal defect occlusion,
and others may be made significantly easier, safer, and more
effective by collaboration with anesthesiologists. Surgical
procedures such as pacemaker placement or lead extraction
are usually done with the patient under anesthesia. The use
of anesthesia is a judgment made by the attending cardiol-
ogist in consultation with the anesthesiologist, just as it is in
surgery. Wide discretion is allowed and encouraged.
4. Procedural Performance Differences Compared
With the Adult Cardiac Catheterization Laboratory.
a. SINGLE-PLANE VERSUS BIPLANE ANGIOGRAPHY. The
standard equipment in a PCCL includes biplane radio-
graphic equipment. In general, pediatric and congenital
cardiac catheterizations are performed using biplane fluo-
roscopy and angiography. This is important both for local-
izing the catheter in space within the heart vessels and for
reduction in contrast dosage administration. Certain proce-
dures can be routinely performed with single-plane fluoros-
copy, including (in many laboratories) electrophysiological
study and radiofrequency ablation, some types of atrial
septal defect occlusion, and others. Atrial septal defect
occlusion is often performed with localization and position-
ing of the device using transesophageal echocardiography as
well as fluoroscopy. Coronary arteriography in children may
be performed with single-plane use, especially if it is assisted
or performed by an adult cardiologist for whom perfor-
mance of single-plane fluoroscopy/angiography might be
standard.
b. HEMODYNAMICS. As noted, right- and left-heart cathe-
terization are performed in combination in many pediatric
and congenital heart catheterization procedures. In addition
to the left ventricular systolic and end-diastolic pressures
and aortic or arterial pressures normally obtained in the
adult cardiac laboratory, right-heart pressures are standard.
Pressure waveforms and determinations of oxygen satura-
tions are generally obtained from each chamber of the heart
entered and from the pulmonary arteries or veins, aorta, or
systemic veins as indicated during any particular procedure.
The routine pressure measurements and recordings neces-
sary are difficult to specify, because they vary widely depend-
ing on the anatomy and physiology involved. For example,
in a patient with pulmonary valve stenosis, a left ventricular
pressure may not be obtained at all, whereas a right
ventricular systolic and diastolic pressure recording is man-
datory. On the other hand, pulmonary artery pressure,
routinely obtained in a right-heart catheterization, may be
difficult to obtain or even ill advised in a patient whose
pulmonary arteries might have to be entered via a tenuous
surgically created shunt. Even an invasive arterial or aortic
pressure might not be obtained in the setting of a cardiac
transplant repeat biopsy or other limited right-heart proce-
dure. Pressures should be able to be recorded with excellent
and reliable fidelity on scales, which range from a full scale
of 10 mm Hg to 400 mm Hg. Rapid availability of oxygen
saturations and blood gases is essential for interpretation of
shunt physiology and patient safety.
c. ANGIOGRAPHIC ACQUISITION DIFFERENCES. Angio-
grams are routinely performed with framing rates ranging
from 15 to 60 fps. The framing rate depends on the patient’s
heart rate and the types of images to be acquired. For
example, during balloon dilation, angiographic images may
be acquired at 15 (or even 7.5) fps, whereas a ventriculogram
in an infant with a high heart rate may require imaging at 30
or 60 fps. A wide variety of catheters, appropriate contrast
materials, and injection techniques and parameters are
available. Contrast is often injected at a faster rate in the
PCCL compared with the adult laboratory, because fine
details of the anatomy are sought rather than global function
or regional wall motion abnormalities. In selected patients,
30 to 40 mL of contrast may be injected over 1 s, for
instance. In addition, in most cases, premature ventricular
beats or even ventricular tachycardia are better tolerated in
younger patients with no ischemic heart disease. Angio-
grams should be available for immediate review after acqui-
sition on some type of “instant replay” digital playback
high-speed disk. Short- and long-term archival of digital
data or cineangiograms does not differ from that described
in prior sections.
d. RADIATION PROTECTION AND THE PREGNANT (OR PO-
TENTIALLY PREGNANT) PATIENT. The same principles of
radiation protection applied in the adult cardiac catheter-
ization laboratory apply in the PCCL. In addition, girls and
young women of child-bearing age should undergo testing
to ensure that they are not pregnant before having a cardiac
catheterization. This might be based on history in some
cases (such as if a patient has an implanted chronic chemical
contraceptive or if she has had a bilateral tubal ligation or
hysterectomy), but it should otherwise include a serum or
urine human chorionic gonadotropin level.
If a pregnant patient must be studied, the abdominal and
groin areas should be shielded to help reduce any direct
X-ray exposure. As noted in the section on radiation
exposure, though, scattered X-rays will still occur and could
be harmful to a newly developing fetus. Efforts to minimize
exposure should include using fluoroscopy or in-laboratory
echocardiography rather than cineangiography, limiting to-
tal exposure time, using reduced framing rates, using the
minimum number of contrast injections, and avoiding
angulated views when possible.
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e. SHUNT MEASUREMENTS. Important information regard-
ing physiology of congenital heart disease is gathered from
measurements of intracardiac shunts. Both right-to-left and
left-to-right shunts must be able to be quantitated during
the catheterization. Because of the need to determine
intracardiac shunting, oxygen saturation samples are drawn
from many sites rather than simply from the pulmonary
artery for mixed venous oxygen level and from the systemic
artery for arterial oxygen level. Therefore, the availability of
oxygen saturation measurements and arterial blood gas
determinations is essential for the efficient performance of
the typical congenital cardiac catheterization. The availabil-
ity of blood gas measurements also allows for the inclusion
of dissolved oxygen in the determination of oxygen content.
Measurement of oxygen consumption should also be avail-
able.
f. LABORATORY PERSONNEL ISSUES. The laboratory staff in
the PCCL should be specifically trained and experienced in
the care of infants and children during performance of a
cardiac catheterization. The specific responsibilities within
the laboratory may necessitate the services of a registered
nurse, a licensed practical or vocational nurse, a radiography
technician, a certified catheterization technician, or others.
It is the responsibility of the director and supervisor of the
Pediatric Cardiac Catheterization Laboratory to ensure
adequate staffing. On-call cases must be considered, and a
complement of personnel adequate for the safe, efficient,
and informative conduct of emergent or urgent pediatric
catheterizations must be available at all times.
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